Publications
2024
Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval—A Case Study Using Levonorgestrel
Cole, S., Pertinez, H., Butler, A. S., Kerwash, E., Bhat, S., El-Khateeb, E., & Owen, A. (n.d.). Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval—A Case Study Using Levonorgestrel. Pharmaceuticals, 17(12). doi:10.3390/ph17121640
Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.
Prasanchaimontri, I. -O., Manosuthi, W., Pertinez, H., Owen, A., Niyomnaitham, S., Sirijatuphat, R., . . . Chokephaibulkit, K. (2024). Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.. Pharmacology research & perspectives, 12(6), e1233. doi:10.1002/prp2.1233
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
Neary, M., Gallardo-Toledo, E., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (n.d.). Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters. Viruses, 16(12). doi:10.3390/v16121838
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.
Furl, R., Scarsi, K. K., Sayles, H., Anderson, M., Ofimboudem, J. D., Weld, E. D., . . . Swindells, S. (2024). Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.. Journal of viral hepatitis. doi:10.1111/jvh.14031
Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.
Kawano-Dourado, L., Kristianslund, E. K., Zeraatkar, D., Jani, M., Makharia, G., Hazlewood, G., . . . Vandvik, P. O. (2024). Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.. BMJ (Clinical research ed.), 387, e079830. doi:10.1136/bmj-2024-079830
Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype.
Eniayewu, O., Akinloye, A., Shenkoya, B., Azuka, U., Bolaji, O., Adejuyigbe, E., . . . Olagunju, A. (2024). Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype.. Pharmacogenetics and genomics, 34(8), 253-260. doi:10.1097/fpc.0000000000000542
The long wait for long-acting HIV prevention and treatment formulations.
Venter, W. D. F., Gandhi, M., Sokhela, S., Sikwese, K., Bygrave, H., Gama, L. D., . . . Hill, A. (2024). The long wait for long-acting HIV prevention and treatment formulations.. The lancet. HIV, 11(10), e711-e716. doi:10.1016/s2352-3018(24)00173-5
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., . . . Owen, A. (2024). Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.. Microbiology spectrum, 12(8), e0391623. doi:10.1128/spectrum.03916-23
Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis.
Zhang, C., Wu, Y., Hutton, A. R. J., Hidayat Bin Sabri, A., Hobson, J. J., Savage, A. C., . . . Donnelly, R. F. (2024). Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis.. International journal of pharmaceutics, 124317. doi:10.1016/j.ijpharm.2024.124317
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19.
Clark, J. J., Penrice-Randal, R., Sharma, P., Dong, X., Pennington, S. H., Marriott, A. E., . . . Stewart, J. P. (2024). Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19.. Viruses, 16(6), 863. doi:10.3390/v16060863
Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.
Gupta, N., Swindells, S., Scarsi, K. K., Furl, R., Thomas, D. L., Weld, E. D., . . . Ward, J. W. (2024). Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.. Journal of viral hepatitis, 31(5), 221-232. doi:10.1111/jvh.13921
Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.
Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1
Tatham, L., Sharp, J., Neary, M., Herriott, J., Kijak, E., Gallardo-Toledo, E., . . . Owen, A. (2024). Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1. Poster session presented at the meeting of The 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024). Denver, US.
Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers
Akinloye, A., Oyedeji, T., Eniayewu, O., Adeagbo, B., Bolaji, O., Rannard, S., . . . Olagunju, A. (n.d.). Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers. Future Pharmacology, 4(1), 163-172. doi:10.3390/futurepharmacol4010011
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using LC-MS/MS
2023
Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.
Liu, C., Hern, F. Y., Shakil, A., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2023). Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.. Journal of materials chemistry. B, 11(48), 11532-11543. doi:10.1039/d3tb02268d
Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.
Kinvig, H., Rajoli, R. K. R., Pertinez, H., Vora, L. K., Volpe-Zanutto, F., Donnelly, R. F., . . . Owen, A. (2023). Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.. Pharmaceutics, 15(12), 2709. doi:10.3390/pharmaceutics15122709
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.
Box, H. J., Sharp, J., Pennington, S. H., Kijak, E., Tatham, L., Caygill, C. H., . . . Owen, A. (2023). Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.. The Journal of antimicrobial chemotherapy, dkad362. doi:10.1093/jac/dkad362
Ex vivo transdermal delivery of 3H-labelled atovaquone solid drug nanoparticles: a comparison of topical, intradermal injection and microneedle assisted administration
Morris, S., Long, M., Savage, A., Owen, A., Rannard, S., & Cauldbeck, H. (n.d.). Ex vivo transdermal delivery of 3H-labelled atovaquone solid drug nanoparticles: a comparison of topical, intradermal injection and microneedle assisted administration. Nanoscale Advances. doi:10.1039/d3na00454f
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.
Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.. Viruses, 15(11), 2161. doi:10.3390/v15112161
Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito.
Balta, V. A., Stiffler, D., Sayeed, A., Tripathi, A. K., Elahi, R., Mlambo, G., . . . Shapiro, T. A. (2023). Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito.. Nature communications, 14(1), 6415. doi:10.1038/s41467-023-42030-x
Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria Chemoprevention.
Scarsi, K. K., Sayles, H., Kapungu, K., Sifuna, P., Ippolito, M. M., Furl, R., . . . Swindells, S. (2023). Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria Chemoprevention.. The American journal of tropical medicine and hygiene, 109(4), 752-760. doi:10.4269/ajtmh.23-0245
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. VIRUSES-BASEL, 15(8). doi:10.3390/v15081744
Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research
Neary, M., Arshad, U., Tatham, L., Pertinez, H., Box, H., Rajoli, R. K. R., . . . Owen, A. (2023). Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1228. doi:10.1016/j.jchromb.2023.123823
The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections
De Neck, S., Penrice-Randal, R., Clark, J. J., Sharma, P., Bentley, E. G., Kirby, A., . . . Kipar, A. (2023). The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections. Viruses, 15(8), 1637. doi:10.3390/v15081637
Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
Chang, Y. S., Li, S. -Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S. P., . . . Ammerman, N. C. (2023). Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 67(7). doi:10.1128/aac.00481-23
Understanding the Degradation of Core-Shell Nanogels Using Asymmetrical Flow Field Flow Fractionation
Niezabitowska, E., Gray, D. M. M., Gallardo-Toledo, E., Owen, A., Rannard, S. P. P., & McDonald, T. O. O. (2023). Understanding the Degradation of Core-Shell Nanogels Using Asymmetrical Flow Field Flow Fractionation. JOURNAL OF FUNCTIONAL BIOMATERIALS, 14(7). doi:10.3390/jfb14070346
Expression of CYP2B6 Enzyme in Human Liver Tissue of HIV and HCV Patients
Obradovic, B., Roberts, O., Owen, A., Milosevic, I., Milic, N., Ranin, J., & Dragovic, G. (2023). Expression of CYP2B6 Enzyme in Human Liver Tissue of HIV and HCV Patients. MEDICINA-LITHUANIA, 59(7). doi:10.3390/medicina59071207
Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.
Curley, P., Hobson, J. J., Liptrott, N. J., Makarov, E., Al-Khouja, A., Tatham, L., . . . Owen, A. (2023). Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.. Pharmaceutics, 15(7), 1835. doi:10.3390/pharmaceutics15071835
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2
Gaynor, K. U. U., Vaysburd, M., Harman, M. A. J., Albecka, A., Jeffrey, P., Beswick, P., . . . James, L. C. C. (2023). Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-39158-1
Layer by layer self-assembly for coating a nanosuspension to modify drug release and stability for oral delivery
Elbaz, N. M., Tatham, L. M., Owen, A., Rannard, S., & McDonald, T. O. (2023). Layer by layer self-assembly for coating a nanosuspension to modify drug release and stability for oral delivery. Food Hydrocolloids, 108908. doi:10.1016/j.foodhyd.2023.108908
Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (vol 23, 583, 2022)
Smith, T. A., Hoyo-Vadillo, C., Adom, A. A., Favari-Perozzi, L., Gastine, S., Dehbi, H. -M., . . . Escobedo, J. (2023). Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) (vol 23, 583, 2022). TRIALS, 24(1). doi:10.1186/s13063-023-07364-3
Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy.
Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.
BUZIBYE, A. L. L. A. N., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.. AIDS Research and Therapy. doi:10.1186/s12981-023-00514-2
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., . . . Sampaziotis, F. (2023). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. NATURE, 615(7950), 134-+. doi:10.1038/s41586-022-05594-0
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.
Cirrincione, L. R., Nakalema, S., Chappell, C. A., Byakika-Kibwika, P., Kyohairwe, I., Winchester, L., . . . Scarsi, K. K. (2023). Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.. Contraception, 109975. doi:10.1016/j.contraception.2023.109975
Transmissibility of clinically relevant atovaquone-resistant Plasmodium falciparum by anopheline mosquitoes.
Balta, V. A., Stiffler, D., Sayeed, A., Tripathi, A. K., Elahi, R., Mlambo, G., . . . Shapiro, T. A. (2023). Transmissibility of clinically relevant atovaquone-resistant Plasmodium falciparum by anopheline mosquitoes.. bioRxiv. doi:10.1101/2023.02.07.527535
Chasing COVID-19 chemotherapeutics without putting the cart before the horse
Rannard, S. P., McDonald, T. O., & Owen, A. (2023). Chasing COVID-19 chemotherapeutics without putting the cart before the horse. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 89(1), 421-423. doi:10.1111/bcp.14575
Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study
Gurjar, R., Dickinson, L., Carr, D., Stohr, W., Bonora, S., Owen, A., . . . Boffito, M. (2022). Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study. PHARMACOGENOMICS JOURNAL. doi:10.1038/s41397-022-00293-5
2022
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study
Sirijatuphat, R., Manosuthi, W., Niyomnaitham, S., Owen, A., Copeland, K. K., Charoenpong, L., . . . Chokephaibulkit, K. (2022). Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. EMERGING MICROBES & INFECTIONS, 11(1), 2197-2206. doi:10.1080/22221751.2022.2117092
WHO Living Guidelines on antivirals for COVID-19 are evidence-based
Owen, A., Diaz, J. V., Guyatt, G., Lamontagne, F., Stegemann, M., Vandvik, P. O., & Agoritsas, T. (2022). WHO Living Guidelines on antivirals for COVID-19 are evidence-based. LANCET, 400(10369), 2196-2198. doi:10.1016/S0140-6736(22)02306-6
Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial
Chandiwana, N., Kruger, C., Johnstone, H., Chughlay, M. F., Ju, C., Kim, B., . . . Venter, W. D. F. (2022). Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. EBIOMEDICINE, 86. doi:10.1016/j.ebiom.2022.104322
A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm
Neary, M., Owen, A., & Olagunju, A. (2022). A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm. Clinical Infectious Diseases, 75(Supplement_4), S490-S497. doi:10.1093/cid/ciac685
Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment
Ammerman, N. C., Nuermberger, E. L., Owen, A., Rannard, S. P., Meyers, C. F., & Swindells, S. (2022). Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment. CLINICAL INFECTIOUS DISEASES, 75, S510-S516. doi:10.1093/cid/ciac672
Prospects for Long-Acting Treatments for Hepatitis C
Thomas, D. L., Owen, A., & Kiser, J. J. (2022). Prospects for Long-Acting Treatments for Hepatitis C. CLINICAL INFECTIOUS DISEASES, 75, S525-S529. doi:10.1093/cid/ciac715
The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases
Flexner, C., Siccardi, M., Bunglawala, F., & Owen, A. (2022). The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases. CLINICAL INFECTIOUS DISEASES, 75, S502-S509. doi:10.1093/cid/ciac750
Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants
Hentzien, M., Owen, A., Strub-Wourgaft, N., Perez-Casas, C., Troseid, M., & Calmy, A. (2022). Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants. FRONTIERS IN MICROBIOLOGY, 13. doi:10.3389/fmicb.2022.998287
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
Sokhela, S., Bosch, B., Hill, A., Simmons, B., Woods, J., Johnstone, H., . . . Venter, W. D. F. (2022). Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(10), 2706-2712. doi:10.1093/jac/dkac266
A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19
Fowotade, A., Bamidele, F., Egbetola, B., Fagbamigbe, A. F., Adeagbo, B. A., Adefuye, B. O., . . . Olagunju, A. (2022). A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. FRONTIERS IN MEDICINE, 9. doi:10.3389/fmed.2022.956123
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
Weld, E. D., Astemborski, J., Kirk, G. D., Sulkowski, M. S., Katz, S., Rothman, R., . . . Thomas, D. L. (2022). Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. CLINICAL INFECTIOUS DISEASES, 75(1), 3-10. doi:10.1093/cid/ciab913
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
Assmus, F., Driouich, J. -S., Abdelnabi, R., Vangeel, L., Touret, F., Adehin, A., . . . Chatelain, E. (2022). Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. MICROORGANISMS, 10(8). doi:10.3390/microorganisms10081639
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
Smith, T., Hoyo-Vadillo, C., Adom, A. A., Favari-Perozzi, L., Gastine, S., Dehbi, H. -M., . . . Escobedo, J. (2022). Favipiravir and/or nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). TRIALS, 23(1). doi:10.1186/s13063-022-06533-0
Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria
Nwogu, J. N., Ngene, S. O., Babalola, C. P., Olagunju, A., Owen, A., Khoo, S. H., . . . Taiwo, B. (2022). Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00462-3
Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants
Shakil, A., Hern, F. Y., Liu, C., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2022). Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. JOURNAL OF MATERIALS CHEMISTRY B, 10(23), 4395-4404. doi:10.1039/d2tb00825d
Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse
Seehusen, F., Clark, J. J., Sharma, P., Bentley, E. G., Kirby, A., Subramaniam, K., . . . Kipar, A. (2022). Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. VIRUSES-BASEL, 14(5). doi:10.3390/v14051020
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463
Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2
Jeffreys, L. N., Pennington, S. H., Duggan, J., Caygill, C. H., Lopeman, R. C., Breen, A. F., . . . Biagini, G. A. (2022). Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 59(3). doi:10.1016/j.ijantimicag.2022.106542
Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells
Sacramento, C. Q., Fintelman-Rodrigues, N., Dias, S. S. G., Temerozo, J. R., Da Silva, A. D. P. D., da Silva, C. S., . . . Souza, T. M. L. (2022). Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. VIRUSES-BASEL, 14(2). doi:10.3390/v14020374
Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
Quinn, T. M., Gaughan, E. E., Bruce, A., Antonelli, J., O'Connor, R., Li, F., . . . Dhaliwal, K. (2022). Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBIOMEDICINE, 76. doi:10.1016/j.ebiom.2022.103856
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2
2021
Impact of long-acting therapies on the global HIV epidemic
Chandiwana, N. C., Serenata, C. M., Owen, A., Rannard, S., Casas, C. P., Scott, C., . . . Flexner, C. (2021). Impact of long-acting therapies on the global HIV epidemic. AIDS, 35, S137-S143. doi:10.1097/QAD.0000000000003102
Redispersible nanosuspensions as a plausible oral delivery system for curcumin
Elbaz, N. M., Tatham, L. M., Owen, A., Rannard, S., & McDonald, T. O. (2021). Redispersible nanosuspensions as a plausible oral delivery system for curcumin. Food Hydrocolloids, 121, 107005. doi:10.1016/j.foodhyd.2021.107005
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318
Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19
Brain, D., Plant-Hately, A., Heaton, B., Arshad, U., David, C., Hedrich, C., . . . Liptrott, N. J. (2021). Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. ADVANCED DRUG DELIVERY REVIEWS, 178. doi:10.1016/j.addr.2021.113848
In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel
Roberts, O., Kinvig, H., Owen, A., Lamorde, M., Siccardi, M., & Scarsi, K. K. (2021). In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV MEDICINE, 22(10), 898-906. doi:10.1111/hiv.13136
Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (n.d.). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 6, 246. doi:10.12688/wellcomeopenres.17202.1
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Huo, J., Mikolajek, H., Le Bas, A., Clark, J. J., Sharma, P., Kipar, A., . . . Moynie, L. (2021). A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-25480-z
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice
Salzer, R., Clark, J. J., Vaysburd, M., Chang, V. T., Albecka, A., Kiss, L., . . . Lowe, J. (2021). Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. FEBS LETTERS, 595(18), 2323-2340. doi:10.1002/1873-3468.14171
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?
Hiscox, J. A., Khoo, S. H., Stewart, J. P., & Owen, A. (2021). Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(9), 2230-2233. doi:10.1093/jac/dkab189
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants
Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles
David, C. A. W., del Castillo Busto, M. E., Cuello-Nunez, S., Goenaga-Infante, H., Barrow, M., Fernig, D. G., . . . Liptrott, N. J. (2021). Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles. CELL AND BIOSCIENCE, 11(1). doi:10.1186/s13578-021-00648-8
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2
Pertinez, H., Rajoli, R. K. R., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2121-2128. doi:10.1093/jac/dkab135
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development
Boffito, M., Back, D. J., Flexner, C., Sjo, P., Blaschke, T. F., Horby, P. W., . . . Owen, A. (2021). Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. CLINICAL PHARMACOLOGY & THERAPEUTICS, 110(1), 64-68. doi:10.1002/cpt.2099
<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
Sacramento, C. Q., Fintelman-Rodrigues, N., Temerozo, J. R., Dias Da Silva, A. D. P., Gomes Dias, S. D. S., da Silva, C. D. S., . . . Souza, T. M. L. (2021). <i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(7), 1874-1885. doi:10.1093/jac/dkab072
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Stachulski, A. V., Taujanskas, J., Pate, S. L., Rajoli, R. K. R., Aljayyoussi, G., Pennington, S. H., . . . O'Neill, P. M. (2021). Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. ACS INFECTIOUS DISEASES, 7(6), 1317-1331. doi:10.1021/acsinfecdis.0c00478
Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria.
Nwogu, J. N., Gandhi, M., Owen, A., Khoo, S., Taiwo, B., Olagunju, A., . . . Babalola, C. P. (2021). Associations between efavirenz concentrations, pharmacogenetics, and neurocognitive performance in people living with HIV in Nigeria.. AIDS (London, England). doi:10.1097/qad.0000000000002984
Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice
Salzer, R., Clark, J., Vaysburd, M., Chang, V., Albecka, A., Kiss, L., . . . Löwe, J. (2021). Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. doi:10.1101/2021.05.18.444622
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309g
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619
A living WHO guideline on drugs to prevent covid-19
Lamontagne, F., Agoritsas, T., Siemieniuk, R., Rochwerg, B., Bartoszko, J., Askie, L., . . . Jacobs, M. (2021). A living WHO guideline on drugs to prevent covid-19. BMJ-BRITISH MEDICAL JOURNAL, 372. doi:10.1136/bmj.n526
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035.v1
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
Pertinez, H., Rajoli, R. K., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.. medRxiv. doi:10.1101/2021.01.03.21249159
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial
Olagunju, A., Fowotade, A., Olagunoye, A., Ojo, T. O., Adefuye, B. O., Fagbamigbe, A. F., . . . Owen, A. (2021). Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 22(1). doi:10.1186/s13063-020-04987-8
Long-acting drugs and formulations for the treatment and prevention of HIV infection
Flexner, C., Owen, A., Siccardi, M., & Swindells, S. (2021). Long-acting drugs and formulations for the treatment and prevention of HIV infection. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 57(1). doi:10.1016/j.ijantimicag.2020.106220
Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events
Hoffmann, C., MacKay, A., Schewe, C. K., Hansen, S., Buhk, T., Fenske, S., . . . Elliot, E. (2021). Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events. In INFECTION Vol. 49 (pp. S21-S22). Retrieved from https://www.webofscience.com/
2020
Remdesivir-ivermectin combination displays synergistic interaction with improved<i>in vitro</i>antiviral activity against SARS-CoV-2
Designing single trigger/dual-response release and degradation into amine-functional hyperbranched-polydendron nanoprecipitates
Rogers, H. E., Chambon, P., Flynn, S., Hern, F. Y., Owen, A., & Rannard, S. P. (2020). Designing single trigger/dual-response release and degradation into amine-functional hyperbranched-polydendron nanoprecipitates. NANOSCALE ADVANCES, 2(11), 5468-5477. doi:10.1039/d0na00696c
Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19
Clark, J., Penrice-Randal, R., Sharma, P., Kipar, A., Dong, X., Pennington, S., . . . Stewart, J. (2020). Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. doi:10.1101/2020.10.13.334532
Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV
Elkateb, H., Tatham, L. M., Cauldbeck, H., Niezabitowska, E., Owen, A., Rannard, S., & McDonald, T. (n.d.). Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV. International Journal of Pharmaceutics, 119794. doi:10.1016/j.ijpharm.2020.119794
Safety perspectives on presently considered drugs for the treatment of COVID‐19
Penman, S. L., Kiy, R. T., Jensen, R. L., Beoku‐Betts, C., Alfirevic, A., Back, D., . . . Chadwick, A. E. (n.d.). Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology. doi:10.1111/bph.15204
A living WHO guideline on drugs for covid-19
Agarwal, A., Hunt, B., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., . . . Vandvik, P. O. (2020). A living WHO guideline on drugs for covid-19. BMJ (Clinical research ed.), 370, m3379. doi:10.1136/bmj.m3379
In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells
David, C. A. W., Barrow, M., Murray, P., Rosseinsky, M. J., Owen, A., & Liptrott, N. J. (n.d.). In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells. International Journal of Molecular Sciences, 21(16), 5610. doi:10.3390/ijms21165610
Chasing COVID-19 chemotherapeutics without putting the cart before the horse
Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients
Dragovic, G., Dimitrijevic, B., Kusic, J., Soldatovic, I., Jevtovic, D., Olagunju, A., & Owen, A. (2020). Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i><sub>trough</sub> in Serbian HIV/AIDS patients. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 86(7), 1289-1295. doi:10.1111/bcp.14230
Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz
Adegbola, A. J., Rana, A., Adeagbo, B. A., Bolarinwa, R. A., Olagunju, A. E., Siccardi, M., . . . Bolaji, O. O. (2020). Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. PHARMACOGENETICS AND GENOMICS, 30(5), 96-106. doi:10.1097/FPC.0000000000000401
Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products
Halamoda-Kenzaoui, B., Box, H., van Elk, M., Gaitan, S., Geertsma, R. E., Gainza Lafuente, E., . . . Bremer-Hoffmann, S. (n.d.). Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products. Precision Nanomedicine, 3(2). doi:10.33218/001c.13521
The<i>in vitro</i>antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2
Sacramento, C., Fintelman-Rodrigues, N., Temerozo, J., de Paula Dias Da Silva, A., da Silva Gomes Dias, S., dos Santos da Silva, C., . . . Souza, T. M. (2020). The<i>in vitro</i>antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2. doi:10.1101/2020.06.15.153411
Safety perspectives on presently considered drugs for the treatment of COVID-19
Pharmacokinetics of HIV therapies in pregnant patients: an update
Neary, M., Owen, A., & Olagunju, A. (2020). Pharmacokinetics of HIV therapies in pregnant patients: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 16(6), 449-461. doi:10.1080/17425255.2020.1754792
Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity
Hobson, J. J., Rannard, S. P., Owen, A., & Liptrott, N. J. (2020). Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity. Nanomedicine. doi:10.2217/nnm-2019-0447
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909
Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.
Rajoli, R. K. R., Demkovich, Z. R., Flexner, C., Owen, A., & Siccardi, M. (2020). Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00155-20
Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130
Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population
Neary, M., Olagunju, A., Sarfo, F., Phillips, R., Moss, D., Owen, A., & Chadwick, D. (2020). Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1267-1271. doi:10.1093/jac/dkaa008
Genetic influence of <i>ABCG2, UGT1A1</i> and <i>NR1I2</i> on dolutegravir plasma pharmacokinetics
Elliot, E. R., Neary, M., Else, L., Khoo, S., Moyle, G., Carr, D. F., . . . Owen, A. (2020). Genetic influence of <i>ABCG2, UGT1A1</i> and <i>NR1I2</i> on dolutegravir plasma pharmacokinetics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1259-1266. doi:10.1093/jac/dkz558
Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection
Aljayyoussi, G., Rajoli, R. K. R., Pertinez, H., Pennington, S., Hong, D., O’Neill, P., . . . Biagini, G. (2020). Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection. doi:10.1101/2020.04.24.20078741
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
Pepperrell, T., Pilkington, V., Owen, A., Wang, J., & Hill, A. M. (2020). Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. JOURNAL OF VIRUS ERADICATION, 6(2), 52-60. Retrieved from https://www.webofscience.com/
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
Pepperrell, T., Pilkington, V., Owen, A., Wang, J., & Hill, A. M. (n.d.). Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Journal of Virus Eradication, 6(2), 52-60.
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379
N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-lsoniazid Pharmacokinetics during Antituberculosis Treatment
Mthiyane, T., Millard, J., Adamson, J., Balakrishna, Y., Connolly, C., Owen, A., . . . Pym, A. S. (2020). N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-lsoniazid Pharmacokinetics during Antituberculosis Treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(4). doi:10.1128/AAC.02376-49
<i>CYP2B6</i>*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). <i>CYP2B6</i>*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. JOURNAL OF CLINICAL PHARMACOLOGY, 60(3), 351-360. doi:10.1002/jcph.1527
Critical considerations for targeting colorectal liver metastases with nanotechnology
Arshad, U., Sutton, P. A., Ashford, M. B., Treacher, K. E., Liptrott, N. J., Rannard, S. P., . . . Owen, A. (2020). Critical considerations for targeting colorectal liver metastases with nanotechnology. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 12(2). doi:10.1002/wnan.1588
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial
Dickinson, L., Gurjar, R., Stoehr, W., Bonora, S., Owen, A., D'Avolio, A., . . . Boffito, M. (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 628-639. doi:10.1093/jac/dkz479
Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling
Bunglawala, F., Rajoli, R. K. R., Mirochnick, M., Owen, A., & Siccardi, M. (2020). Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 640-647. doi:10.1093/jac/dkz506
Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G>T Genotypes
Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G>T Genotypes. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(3). doi:10.1128/AAC.00947-19
Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multi-layered nanocapsules for oral drug delivery
Elbaz, N. M., Owen, A., Rannard, S., & McDonald, T. O. (2020). Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multi-layered nanocapsules for oral drug delivery. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 574. doi:10.1016/j.ijpharm.2019.118866
N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.
Mthiyane, T., Millard, J., Adamson, J., Balakrishna, Y., Connolly, C., Owen, A., . . . Pym, A. S. (2020). N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.02376-19
HIV, ART and COVID-19: interplay and interactions
Sabin, C., Waters, L., Sparrowhawk, A., Owen, A., & Cevik, M. (2020). HIV, ART and COVID-19: interplay and interactions. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 23 (pp. 13). Retrieved from https://www.webofscience.com/
2019
N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid /<i>N</i>-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies
Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068
Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations
Hobson, J. J., Curley, P., Savage, A. C., Al-khouja, A., Siccardi, M., Flexner, C., . . . Rannard, S. P. (2019). Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. NANOSCALE ADVANCES, 1(11), 4301-4307. doi:10.1039/c9na00529c
Meta-analysis of the effect of <i>CYP2B6, CYP2A6, UGT2B7</i> and <i>CAR</i> polymorphisms on efavirenz plasma concentrations
Ayuso, P., Neary, M., Chiong, J., & Owen, A. (2019). Meta-analysis of the effect of <i>CYP2B6, CYP2A6, UGT2B7</i> and <i>CAR</i> polymorphisms on efavirenz plasma concentrations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(11), 3281-3290. doi:10.1093/jac/dkz329
Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK
Rajoli, R. K. R., Flexner, C., Chiong, J., Owen, A., Donnelly, R. F., Larraneta, E., & Siccardi, M. (2019). Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 144, 101-109. doi:10.1016/j.ejpb.2019.09.011
Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART
Neary, M., Chappell, C. A., Scarsi, K. K., Nakalema, S., Matovu, J., Achilles, S. L., . . . Lamorde, M. (2019). Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(10), 3003-3010. doi:10.1093/jac/dkz298
On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019)
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019). NATURE NANOTECHNOLOGY, 14(9), 902. doi:10.1038/s41565-019-0538-3
On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019)
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine (vol 14, pg 629, 2019). NATURE NANOTECHNOLOGY, 14(8), 811. doi:10.1038/s41565-019-0523-x
Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?
Tatham, L. M., Liptrott, N. J., Rannard, S. P., & Owen, A. (2019). Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?. MOLECULES, 24(15). doi:10.3390/molecules24152685
On the issue of transparency and reproducibility in nanomedicine
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufes, C., . . . Pastore, C. (2019). On the issue of transparency and reproducibility in nanomedicine. NATURE NANOTECHNOLOGY, 14(7), 629-635. doi:10.1038/s41565-019-0496-9
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide
Cerrone, M., Alfarisi, O., Neary, M., Marzinke, M. A., Parsons, T. L., Owen, A., . . . Boffito, M. (2019). Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1670-1678. doi:10.1093/jac/dkz068
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726
Improving maraviroc oral bioavailability by formation of solid drug nanoparticles
Savage, A. C., Tatham, L. M., Siccardi, M., Scott, T., Vourvahis, M., Clark, A., . . . Owen, A. (2019). Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 30-36. doi:10.1016/j.ejpb.2018.05.015
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019)
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(5), 1466. doi:10.1093/jac/dky571
Towards a Maraviroc long-acting injectable nanoformulation
Tatham, L. M., Savage, A. C., Dwyer, A., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2019). Towards a Maraviroc long-acting injectable nanoformulation. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 92-98. doi:10.1016/j.ejpb.2018.04.009
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
Francis, J., Zvada, S. P., Denti, P., Hatherill, M., Charalambous, S., Mungofa, S., . . . McIlleron, H. M. (2019). A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(4). doi:10.1128/AAC.01964-18
Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies
Hobson, J., Al-Khouja, A., Curley, P., Flexner, C., Meyers, C., Owen, A., & Rannard, S. (2017). Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
Hobson, J., Al-Khouja, A., Curley, P., Meyers, D., Flexner, C., Siccardi, M., . . . Rannard, S. P. (2019). Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nature Communications, 10. doi:10.1038/s41467-019-09354-z
A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
Kaboggoza, J. P., Wang, X., Neary, M., Ayuso, P., Sekaggya-Wiltshire, C., Nakalema, S., . . . Boffito, M. (2019). A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. OPEN FORUM INFECTIOUS DISEASES, 6(2). doi:10.1093/ofid/ofz035
Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals
Cerrone, M., Wang, X., Neary, M., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (2019). Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. CLINICAL INFECTIOUS DISEASES, 68(3), 446-452. doi:10.1093/cid/ciy491
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
Abdullahi, S. T., Olagunju, A., Soyinka, J. O., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2019). Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?. British journal of clinical pharmacology. doi:10.1111/bcp.13821
Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multilayered nanocapsules for oral drug delivery
Elbaz, N., Owen, A., Rannard, S., & McDonald, T. (2019). Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multilayered nanocapsules for oral drug delivery. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 258. Retrieved from https://www.webofscience.com/
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Elliot, E. R., Cerrone, M., Else, L., Amara, A., Bisdomini, E., Khoo, S., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.. The Journal of antimicrobial chemotherapy, 74(1), 149-156. doi:10.1093/jac/dky384
Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study
Olagunju, A., Anweh, D., Okafor, O., Dickinson, L., Richman, D., Owen, A., & Adejuyigbe, E. (2019). Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study. doi:10.12688/wellcomeopenres.15072.1
2018
Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro
Gurjar, R., Chan, C. Y. S., Curley, P., Sharp, J., Chiong, J., Rannard, S., . . . Owen, A. (2018). Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. MOLECULAR PHARMACEUTICS, 15(11), 4835-4842. doi:10.1021/acs.molpharmaceut.8b00482
Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.
Keshavjee, S., Amanullah, F., Cattamanchi, A., Chaisson, R., Dobos, K. M., Fox, G. J., . . . Nahid, P. (2018). Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.. American journal of respiratory and critical care medicine. doi:10.1164/rccm.201806-1053pp
Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection
Adegbola, A., Abutaima, R., Olagunju, A., Ijarotimi, O., Siccardi, M., Owen, A., . . . Bolaji, O. (2018). Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(10). doi:10.1128/AAC.01252-18
Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions
Hern, F. Y., Tatham, L., Owen, A., & Rannard, S. (2018). Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions. In 256th National Meeting and Exposition of the American-Chemical-Society (ACS) - Nanoscience, Nanotechnology and Beyond Vol. 256. Boston, MA.
Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir
Savage, A., Ashcroft, S., Box, H., Sharp, J., Neary, M., Owen, A., & Rannard, S. (2018). Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum
Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika-Kibwika, P., . . . Boffito, M. (2018). Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. CLINICAL INFECTIOUS DISEASES, 67(5), 785-790. doi:10.1093/cid/ciy161
Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach
Chan, C. Y. S., Roberts, O., Rajoli, R. K. R., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2018). Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. DRUG METABOLISM AND PHARMACOKINETICS, 33(4), 179-187. doi:10.1016/j.dmpk.2018.01.004
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study
Rajoli, R. K. R., Podany, A. T., Moss, D. M., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2018). Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(8), 937-944. doi:10.5588/ijtld.17.0515
The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV
Hobson, J. J., Owen, A., & Rannard, S. P. (2018). The potential value of nanomedicine and novel oral dosage forms in the treatment of HIV. NANOMEDICINE, 13(16), 1963-1965. doi:10.2217/nnm-2018-0182
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18
The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation
Siccardi, M., Rannard, S., & Owen, A. (2018). The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. Advanced Drug Delivery Reviews, 131, 116-121. doi:10.1016/j.addr.2018.06.016
Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 1(16). doi:10.12688/aasopenres.12860.1
Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.
Pushpakom, S. P., Adaikalakoteswari, A., Owen, A., Back, D. J., Tripathi, G., Kumar, S., . . . Pirmohamed, M. (2018). Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.. Diabetes & vascular disease research, 15(3), 233-242. doi:10.1177/1479164118757924
Branched copolymer-stabilised nanoemulsions as new candidate oral drug delivery systems
Hobson, J., Edwards, S., Slater, R., Martin, P., Owen, A., & Rannard, S. P. (2018). Branched copolymer-stabilised nanoemulsions as new candidate oral drug delivery systems. RSC Advances. doi:10.1039/c8ra01944d
Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens
Al-Khouja, A., Hobson, J., Meyers, D., Curley, P., Siliciano, J., Siliciano, R., . . . Meyers, C. (2017). Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515
Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease
Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17
Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2018). Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. JOURNAL OF NANOBIOTECHNOLOGY, 16. doi:10.1186/s12951-018-0349-y
Co-initiated hyperbranched-polydendron building blocks for the direct nanoprecipitation of dendron-directed patchy particles with heterogeneous surface functionality
Rannard, S. P., Owen, A., & Hern, F. (2018). Co-initiated hyperbranched-polydendron buildingblocks for the direct nanoprecipitation ofdendron-directed patchy particles withheterogeneous surface functionality. Polymer Chemistry. doi:10.1039/C8PY00291F
Maraviroc solid drug nanoparticles with improved oral pharmacokinetics
Tatham, L., Savage, A. C., Dwyer, A. B., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Maraviroc solid drug nanoparticles with improved oral pharmacokinetics. In CROI. Boston MA.
Towards a Long-Acting Injectable (LAI) Formulation For Maraviroc
Tatham, L., Dwyer, A. B., Savage, A. C., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Towards a Long-Acting Injectable (LAI) Formulation For Maraviroc. In CROI. Boston MA.
ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.
Elliot, E., Neary, M. G., Else, L., Khoo, S., Moyle, G., Carr, D., . . . Boffito, M. (n.d.). ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.. In CROI. Boston, MA, USA.
CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.
Neary, M. G., Chappell, C., Scarsi, K., Nakalema, S., Matovu, J., Achilles, S., . . . Lamorde, M. (2018, March 5). CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.. In CROI. Boston, MA, USA.
Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV.
Cerrone, M., Xinhu, W., Neary, M. G., Weaver, C., Fedele, S., Day-Weber, I., . . . Boffito, M. (n.d.). Pharmacokinetics of efavirenz 400mg with isoniazid/rifampicin in people with HIV.. In CROI. Boston, MA, USA.
Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.
Box, H., Sharp, J., Neary, M. G., Moss, D., Tatham, L., Savage, A., . . . Owen, A. (n.d.). Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.. In CROI. Boston, MA, USA.
Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics.
Cerrone, M., Alfarisi, O., Neary, M. G., Marzinke, O., Parsons, T., Owen, A., . . . Boffito, M. (n.d.). Rifampin effect on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics.. In CROI. Boston, MA, USA.
The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery
Moss, D. M., Curley, P., Kinvig, H., Hoskins, C., & Owen, A. (2018). The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 12(3), 223-236. doi:10.1080/17474124.2018.1399794
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. F., Flexner, C., Owen, A., & Siccardi, M. (2018). In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.. Clinical pharmacokinetics, 57(02), 255-266. doi:10.1007/s40262-017-0557-x
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges
Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., . . . Flexner, C. (2018). Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(2), 125-132. doi:10.5588/ijtld.17.0486
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Bakshi, R. P., Tatham, L. M., Savage, A. C., Tripathi, A. K., Mlambo, G., Ippolito, M. M., . . . Shapiro, T. A. (2018). Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nature Communications, 9. doi:10.1038/s41467-017-02603-z
Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs
Waitt, C., Olagunju, A., Nakalema, S., Kyohaire, I., Owen, A., Lamorde, M., & Khoo, S. (2018). Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs. Journal of Antimicrobial Chemotherapy, 73(4), 1013-1019. doi:10.1093/jac/dkx507
Advances in nanomedicine drug delivery applications for HIV therapy
Curley, P., Liptrott, N. J., & Owen, A. (2018). Advances in nanomedicine drug delivery applications for HIV therapy. FUTURE SCIENCE OA, 4(1). doi:10.4155/fsoa-2017-0069
Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens
Al-Khouja, A., Hobson, J. J., Henriquez, S., Meyers, D., Curley, P., Siccardi, M., . . . Meyers, C. L. F. (2018). Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. In FASEB JOURNAL Vol. 32. Retrieved from https://www.webofscience.com/
Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions
Hern, F., Tatham, L., Owen, A., & Rannard, S. (2018). Direct synthesis of nanoparticles with spatial heterogeneity for tailored cellular interactions. Retrieved from https://www.webofscience.com/
Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling
Olagunju, A., Schipani, A., Bolaji, O., Khoo, S., & Owen, A. (2018). Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(1), 165-172. doi:10.1093/jac/dkx334
LONG-ACTING INJECTABLE ATOVAQUONE NANOMEDICINES FOR MALARIA PROPHYLAXIS
Bakshi, R., Tatham, L., Savage, A., Tripathi, A., Mlambo, G., Ippolito, M., . . . Shapiro, T. (2018). LONG-ACTING INJECTABLE ATOVAQUONE NANOMEDICINES FOR MALARIA PROPHYLAXIS. In AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Vol. 99 (pp. 94). Retrieved from https://www.webofscience.com/
Potential for immune modulation by inhibition of autophagic processes.
David, C., Owen, A., & Liptrott, N. J. (2018). Potential for immune modulation by inhibition of autophagic processes.. Poster session presented at the meeting of Nanomedicine's Early Career Researchers Meeting. London.
Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling
Saeheng, T., Na-Bangchang, K., Rajoli, R. K. R., Siccardi, M., Owen, A., & Laothavorn, J. (2018). Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. Proceedings for Annual Meeting of The Japanese Pharmacological Society, WCP2018(0). doi:10.1254/jpssuppl.wcp2018.0_po1-11-30
Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage
Hobson, J., Curley, P., Al-khouja, A., Siccardi, M., Flexner, C., Meyers, C., . . . Rannard, S. (2018). Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
2017
Pharmacogenetic considerations for HIV treatment in different ethnicities: an update
Neary, M., & Owen, A. (2017). Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 13(11), 1169-1181. doi:10.1080/17425255.2017.1391214
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
Chan, C., Martin, P., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2017). Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. PHARMACOLOGY RESEARCH & PERSPECTIVES, 5(5). doi:10.1002/prp2.359
In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line
Curley, P., Giardiello, M., Liptrott, N. J., Dickens, D., Moss, D. M., Hobson, J. J., . . . Owen, A. (2017). In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2(3), 157-169. doi:10.1002/jin2.32
Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity
Donnellan, S., Stone, V., Johnston, H., Giardiello, M., Owen, A., Rannard, S., . . . Stevenson, K. (2017). Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity. Journal of Interdisciplinary Nanomedicine, 2(3), 146-156. doi:10.1002/jin2.27
Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2017). Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. NANOMEDICINE, 12(17), 2043-2054. doi:10.2217/nnm-2017-0095
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667
Maraviroc Solid Drug Nanoparticles with Improved Oral Pharmacokinetics
Tatham, L., Savage, A., Rannard, S., & Owen, A. (2017). Maraviroc Solid Drug Nanoparticles with Improved Oral Pharmacokinetics. In British Society for Nanomedicine. Queens University Belfast.
Transdermal delivery with microneedle patches using in silico modelling
Rajoli, R. K. R., Flexner, C., Owen, A., Donnelly, R., & Siccardi, M. (2017). Transdermal delivery with microneedle patches using in silico modelling. Belfast.
Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis
Sloan, D. J., McCallum, A. D., Schipani, A., Egan, D., Mwandumba, H. C., Ward, S. A., . . . Davies, G. R. (2017). Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00210-17
Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate
Moss, D. M., Domanico, P., Watkins, M., Park, S., Randolph, R., Wring, S., . . . Owen, A. (2017). Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00105-17
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat <i>In Vitro</i>
Roberts, O., Khoo, S., Owen, A., & Siccardi, M. (2017). Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(5). doi:10.1128/AAC.01776-16
Foreword
Owen, A. (2017). Foreword. Journal of Interdisciplinary Nanomedicine, 2(1), 4. doi:10.1002/jin2.23
Modulation of inflammasome activation through manipulation of autophagic processes in primary human immune cells.
David, C., Ahmed, F., Owen, A., & Liptrott, N. (2017). Modulation of inflammasome activation through manipulation of autophagic processes in primary human immune cells.. Journal of Interdisciplinary Nanomedicine.
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485
ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.
Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (n.d.). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.
Current Progress in the Pharmacogenetics of Infectious Disease Therapy
Elliot, E., Mahungu, T., & Owen, A. (2017). Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In GENETICS AND EVOLUTION OF INFECTIOUS DISEASES, 2ND EDITION (pp. 435-457). doi:10.1016/B978-0-12-799942-5.00019-6
Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines
Rosslein, M., Liptrott, N. J., Owen, A., Boisseau, P., Wick, P., & Herrmann, I. K. (2017). Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines. NANOTOXICOLOGY, 11(2), 147-149. doi:10.1080/17435390.2017.1279361
19 Current Progress in the Pharmacogenetics of Infectious Disease Therapy
Elliot, E., Mahungu, T., & Owen, A. (2017). 19 Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In Genetics and Evolution of Infectious Diseases (pp. 435-457). Elsevier. doi:10.1016/b978-0-12-799942-5.00019-6
A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo
Silva, A. H., Lima, E. J., Mansilla, M. V., Zysler, R. D., Mojica Pisciotti, M. L., Locatelli, C., . . . Siccardi, M. (2017). A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. EUROPEAN JOURNAL OF NANOMEDICINE, 9(2), 79-90. doi:10.1515/ejnm-2017-0001
Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.
David, C., Giardiello, M., Rannard, S. P., Owen, A., & Liptrott, N. J. (2017). Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.. Poster session presented at the meeting of BSNM Early Career Researchers' Meeting. Belfast.
Efavirenz Is Predicted To Accumulate in Brain Tissue: an <i>In Silico</i>, <i>In Vitro</i>, and <i>In Vivo</i> Investigation
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an <i>In Silico</i>, <i>In Vitro</i>, and <i>In Vivo</i> Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16
Effect of diurnal variation, <i>CYP2B6</i> genotype and age on the pharmacokinetics of nevirapine in African children
Bienczak, A., Cook, A., Wiesner, L., Mulenga, V., Kityo, C., Kekitiinwa, A., . . . Denti, P. (2017). Effect of diurnal variation, <i>CYP2B6</i> genotype and age on the pharmacokinetics of nevirapine in African children. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(1), 190-199. doi:10.1093/jac/dkw388
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients
Sandkovsky, U., Podany, A. T., Fletcher, C. V., Owen, A., Felton-Coleman, A., Winchester, L. C., . . . Swindells, S. (2017). Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(1), 200-204. doi:10.1093/jac/dkw403
Integrated pharmacokinetic modelling for accelerated nanomedicine translation
Siccardi, M., Löffler, B., Balogh, L., & Owen, A. (2017). Integrated pharmacokinetic modelling for accelerated nanomedicine translation. European Journal of Nanomedicine, 9(1), 1-3. doi:10.1515/ejnm-2016-0041
Long acting injectable formulations of atovaquone for malaria prophylaxis
Savage, A., Tatham, L., Bakshi, R., Tripathi, A., Mlambo, G., Shapiro, T., . . . Rannard, S. (2017). Long acting injectable formulations of atovaquone for malaria prophylaxis. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
New branched polymer architectures for nano and macro emulsion stabilisation and targeting/delivery of therapeutic molecules
Hobson, J., Edwards, S., Owen, A., & Rannard, S. (2017). New branched polymer architectures for nano and macro emulsion stabilisation and targeting/delivery of therapeutic molecules. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum
Lamorde, M., Wang, X., Neary, M., Bisdomini, E., Nakalema, S., Byakika, P., . . . Boffito, M. (2017). Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 122). Retrieved from https://www.webofscience.com/
Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines
Giardiello, M., McDonald, T., Liptrott, N., Martin, P., Smith, D., Siccardi, M., . . . Rannard, S. (2017). Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot
Hobson, J., Curley, P., Al-khouja, A., Meyers, C., Flexner, C., Owen, A., & Rannard, S. (2017). Solid drug nanoparticles synthesised using water-in-oil emulsion templating and nanoprecipitation: From proof of concept to in vitro validation of long acting depot. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/
USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES
Chan, C. Y., Roberts, O., Hassan, N., Liptrott, N., Siccardi, M., Almond, L., & Owen, A. (2017). USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES. In DRUG METABOLISM AND PHARMACOKINETICS Vol. 32 (pp. S109). doi:10.1016/j.dmpk.2016.10.099
2016
Computational Predictive Models for Nanomedicine
Siccardi, M., Schipani, A., & Owen, A. (n.d.). Computational Predictive Models for Nanomedicine. In Pharmaceutical Nanotechnology: Innovation and Production: Innovation and Production (pp. 379-402). Wiley-VCH Verlag GmbH & Co. KGaA.
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling
Rajoli, R. K. R., Podany, A., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling. Liverpool.
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
Giardiello, M., Liptrott, M. J., McDonald, T. O., Moss, D., Siccardi, M., Martin, P., . . . Owen, A. (2016). Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7. doi:10.1038/ncomms13184
Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices
Curley, P., Siccardi, M., Moss, D. M., & Owen, A. (2016). Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. BIOANALYSIS, 8(20), 2125-2134. doi:10.4155/bio-2016-0021
Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.
Siccardi, M., Martin, P., Smith, D., Curley, P., McDonald, T., Giardiello, M., . . . Owen, A. (2016). Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.. Journal of interdisciplinary nanomedicine, 1(3), 110-123. doi:10.1002/jin2.21
Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma
McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2016). Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma. HIV CLINICAL TRIALS, 17(5), 197-203. doi:10.1080/15284336.2016.1210719
Long-acting injectable formulations for children and adolescents using PBPK modelling
Rajoli, R. K. R., Back, D., Rannard, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Long-acting injectable formulations for children and adolescents using PBPK modelling. Swansea.
Abstract
Abstract (2016). In Journal of Interdisciplinary Nanomedicine Vol. 1 (pp. 35-82). Wiley. doi:10.1002/jin2.14
Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles
Savage, A. C., Giardiello, M., Owen, A., & Rannard, S. (2016). Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles. In British Society of Nanomedicine Early Career Meeting Vol. 1 (pp. 78). Swansea University. doi:10.1002/jin2.14
Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study
Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
Owen, A., & Rannard, S. (2016). Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. ADVANCED DRUG DELIVERY REVIEWS, 103, 144-156. doi:10.1016/j.addr.2016.02.003
Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers
Tatham, L., Ford, J., Rogers, H., Rannard, S., & Owen, A. (2016). Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers. In Controlled Release Society Annual Meeting & Exposition. Seattle, Washington.
Surface-Dependent Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers
Tatham, L., Ford, J., Rogers, H., Rannard, S., & Owen, A. (2016). Surface-Dependent Mechanism for Transcellular Permeation of Polymeric Nanoparticles Across Intestinal Monolayers. In Controlled Release Society Annual Meeting & Exposition. Seattle, Washington.
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5
Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles
Savage, A. C., Giardiello, M., Owen, A., & Rannard, S. P. (2016). Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles. Poster session presented at the meeting of Royal Society of Chemistry Early Career Symposium. University of Strathclyde.
Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches
David, C. A. W., Owen, A., & Liptrott, N. J. (2016). Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches. NANOMEDICINE, 11(11), 1447-1464. doi:10.2217/nnm-2016-0017
Foreword
Owen, A. (2016). Foreword. Journal of Interdisciplinary Nanomedicine, 1(2), 34. doi:10.1002/jin2.15
Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis
Olagunju, A., Khoo, S., & Owen, A. (2016). Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. PHARMACOGENOMICS, 17(8), 891-906. doi:10.2217/pgs-2015-0016
Validation of computational approaches for antiretroviral dose optimization
Siccardi, M., Dickinson, L., & Owen, A. (n.d.). Validation of computational approaches for antiretroviral dose optimization. Antimicrobial Agents and Chemotherapy, 60, 3838-3839. doi:10.1128/AAC.00094-16
Interdisciplinary Nanomedicine Publications through Interdisciplinary Peer-Review
Owen, A., Rannard, S. P., Bawa, R., & Feng, S. -S. (2016). Interdisciplinary Nanomedicine Publications through Interdisciplinary Peer-Review. In HANDBOOK OF CLINICAL NANOMEDICINE: LAW, BUSINESS, REGULATION, SAFETY, AND RISK (Vol. 2, pp. 1223-1237). Retrieved from https://www.webofscience.com/
Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields
Giardiello, M., Hatton, F. L., Slater, R. A., Chambon, P., North, J., Peacock, A. K., . . . Rannard, S. P. (2016). Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields. Nanoscale, 8(13), 7224-7231. doi:10.1039/c6nr00788k
Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016)
Siccardi, M., Dickinson, L., & Owen, A. (2016). Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). Retrieved from http://gateway.webofknowledge.com/
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake
Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425
Handbook of Immunological Properties of Engineered Nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (n.d.). Handbook of Immunological Properties of Engineered Nanomaterials. WORLD SCIENTIFIC. doi:10.1142/9677
Interdisciplinary nanomedicine publications through interdisciplinary peer-review
Owen, A., Rannard, S., Bawa, R., & Feng, S. -S. (2016). Interdisciplinary nanomedicine publications through interdisciplinary peer-review. Journal of Interdisciplinary Nanomedicine, 1(1), 4-8. doi:10.1002/jin2.1
Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles
Silva, A. H., Locatelli, C., Filippin-Monteiro, F. B., Martin, P., Liptrott, N. J., Zanetti-Ramos, B. G., . . . Creczynski-Pasa, T. B. (2016). Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. TOXICOLOGY LETTERS, 246, 17-27. doi:10.1016/j.toxlet.2016.01.018
Emerging nanomedicine applications and manufacturing: progress and challenges
Sartain, F., Greco, F., Hill, K., Rannard, S., & Owen, A. (2016). Emerging nanomedicine applications and manufacturing: progress and challenges. NANOMEDICINE, 11(6), 577-580. doi:10.2217/nnm.16.17
Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery
Liptrott, N. J., Curley, P., Tatham, L. M., & Owen, A. (2016). Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. In Frontiers in Nanobiomedical Research (pp. 205-239). WORLD SCIENTIFIC. doi:10.1142/9789813140479_0009
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2016). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. Poster session presented at the meeting of Conference on Retroviral and Opportunistic Infections. Boston, MA, USA.
Solid drug nanoparticles: Methods for production and pharmacokinetic benefits
Owen, A., & Rannard, S. P. (2016). Solid drug nanoparticles: Methods for production and pharmacokinetic benefits. In Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications (Vol. 1, pp. 211-232). doi:10.4032/9789814669214
Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.
Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (n.d.). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.
Association of SLCO1B1 521T > C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study
Gurjar, R., Boffito, M., D'Avolio, A., Schwimmer, C., Yazdanpanah, Y., Doroana, M., . . . Owen, A. (2016). Association of SLCO1B1 521T > C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.
David, C., Owen, A., & Liptrott, N. J. (2016). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of University of Liverpool ITM Research Day. Liverpool.
Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis
Hennig, S., Naiker, S., Reddy, T., Egan, D., Kellerman, T., Wiesner, L., . . . Pym, A. (2016). Effect of <i>SLCO1B1</i> Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 617-620. doi:10.1128/AAC.01195-15
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. (2016). Journal of the International AIDS Society, 19(8(Suppl 7)), 21487. doi:10.7448/ias.19.8.21487
Intracellular Transport and Unpacking of Polyplex Nanoparticles
Rosenkranz, A. A., Khramtsov, Y. V., Ulasov, A. V., Rodichenko, N., & Sobolev, A. S. (2016). Intracellular Transport and Unpacking of Polyplex Nanoparticles. In HANDBOOK OF CLINICAL NANOMEDICINE: LAW, BUSINESS, REGULATION, SAFETY, AND RISK (Vol. 2, pp. 823-843). Retrieved from https://www.webofscience.com/
The Challenge of Regulating Nanomedicine: Key Issues
Bawa, R., Barenholz, Y., & Owen, A. (2016). The Challenge of Regulating Nanomedicine: Key Issues. In NANOMEDICINES: DESIGN, DELIVERY AND DETECTION (Vol. 51, pp. 290-314). Retrieved from https://www.webofscience.com/
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
Bienczak, A., Cook, A., Wiesner, L., Olagunju, A., Mulenga, V., Kityo, C., . . . Denti, P. (2016). The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 82(1), 185-198. doi:10.1111/bcp.12934
Towards a computational prediction of nanoparticle pharmacokinetics and distribution
Siccardi, M., & Owen, A. (n.d.). Towards a computational prediction of nanoparticle pharmacokinetics and distribution. Journal of In Silico & In Vitro Pharmacology, 02(01). doi:10.21767/2469-6692.10008
2015
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. L. F., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. CLINICAL PHARMACOKINETICS, 54(6), 639-650. doi:10.1007/s40262-014-0227-1
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment
Nelson, A. G., Zhang, X., Ganapathi, U., Szekely, Z., Flexner, C. W., Owen, A., & Sinko, P. J. (2015). Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. JOURNAL OF CONTROLLED RELEASE, 219, 669-680. doi:10.1016/j.jconrel.2015.08.042
Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation
Naisbitt, D., Yang, E. L., Alhaidari, M., Berry, N., Lawrenson, A. S., Farrell, J., . . . Park, B. (2015). Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. AIDS, 29(18), 2385-2395. doi:10.1097/QAD.0000000000000867
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models
Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/
Class-specific relative genetic contribution for key antiretroviral drugs
Siccardi, M., Olagunju, A., Simiele, M., D'Avolio, A., Calcagno, A., Di Perri, G., . . . Owen, A. (2015). Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 70(11), 3074-3079. doi:10.1093/jac/dkv207
Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles
Martin, P., Giardiello, M., McDonald, T. C., Smith, D., Siccardi, M., Rannard, S. P., & Owen, A. (2015). Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. MOLECULAR PHARMACEUTICS, 12(10), 3556-3568. doi:10.1021/acs.molpharmaceut.5b00204
Considerations for clinically-relevant nanomedicine therapies for chronic diseases
Owen, A., & Rannard, S. (2015). Considerations for clinically-relevant nanomedicine therapies for chronic diseases. NANOMEDICINE, 10(20), 3103-3107. doi:10.2217/nnm.15.135
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174
Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons
Rogers, H. E., Chambon, P., Auty, S. E. R., Hern, F. Y., Owen, A., & Rannard, S. P. (2015). Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons. SOFT MATTER, 11(35), 7005-7015. doi:10.1039/c5sm00673b
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156
Formulation of Solid Drug Nanoparticles for the Improved Oral Bioavailability of Antiretroviral Drugs
Savage, A. C., Tatham, L. M., Owen, A., & Rannard, S. P. (2015). Formulation of Solid Drug Nanoparticles for the Improved Oral Bioavailability of Antiretroviral Drugs. Poster session presented at the meeting of British Society of Nanomedicine Young Researchers Meeting. University of Liverpool.
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317
Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research
McIlleron, H., Abdel-Rahman, S., Dave, J. A., Blockman, M., & Owen, A. (2015). Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research. JOURNAL OF INFECTIOUS DISEASES, 211, S115-S125. doi:10.1093/infdis/jiu600
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
The Application of Nanotechnology to Drug Delivery in Medicine
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5
Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry
Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions
Liptrott, N. J., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2015). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. NANOMEDICINE, 10(9), 1407-1421. doi:10.2217/NNM.14.77
Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial
Winston, A., Amin, J., Clarke, A., Else, L., Amara, A., Owen, A., . . . Puls, R. (2015). Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60(7), 1026-1032. doi:10.1093/cid/ciu976
Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics
Tatham, L. M., Rannard, S. P., & Owen, A. (2015). Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. THERAPEUTIC DELIVERY, 6(4), 469-490. doi:10.4155/TDE.15.4
No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults
Sirirungsi, W., Urien, S., Harrison, L., Kamkon, J., Tawon, Y., Luekamlung, N., . . . Cressey, T. R. (2015). No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 68(4), E56-E59. doi:10.1097/QAI.0000000000000504
Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and A-B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media
Ford, J., Chambon, P., North, J., Hatton, F. L., Giardiello, M., Owen, A., & Rannard, S. P. (2015). Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and A-B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media. MACROMOLECULES, 48(6), 1883-1893. doi:10.1021/acs.macromol.5b00099
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.. The Journal of antimicrobial chemotherapy, 70(2), 555-561.
Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). Chapter 2.2 The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.
David, C., Owen, A., & Liptrott, N. J. (2015). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of European Nanomedicine Meeting. Grenoble.
Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium
Hatton, F. L., Tatham, L. M., Tidbury, L. R., Chambon, P., He, T., Owen, A., & Rannard, S. P. (2015). Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. CHEMICAL SCIENCE, 6(1), 326-334. doi:10.1039/c4sc02889a
Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
Moss, D. M., Liptrott, N. J., Siccardi, M., & Owen, A. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. FRONTIERS IN PHARMACOLOGY, 6. doi:10.3389/fphar.2015.00078
Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.
David, C., Liptrott, N. J., & Owen, A. (2015). Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.. Poster session presented at the meeting of University of Liverpool Poster Day. Liverpool.
Optimisation of methodology to assess the impact of nanomaterials on autophagy.
David, C., Owen, A., & Liptrott, N. J. (2015). Optimisation of methodology to assess the impact of nanomaterials on autophagy.. Poster session presented at the meeting of BSNM Young Researcher Meeting. Liverpool.
Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8
Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.
David, C., Raymant, M. L., Owen, A., & Liptrott, N. J. (2015). Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.. Poster session presented at the meeting of Nanotechnology in Medicine. Manchester.
pH-Responsive hyperbranched-polydendrons for drug delivery applications
Rogers, H., Tatham, L., Chambon, P., Owen, A., & Rannard, S. (2015). pH-Responsive hyperbranched-polydendrons for drug delivery applications. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 250. Retrieved from https://www.webofscience.com/
2014
<i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). <i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. THERAPEUTIC DRUG MONITORING, 36(6), 734-738. doi:10.1097/FTD.0000000000000098
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(12), 3275-3281. doi:10.1093/jac/dku312
A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69(12), 3275-3281. doi:10.1093/jac/dku312
Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'. Nanomedicine, 9(16), 2467-2479. doi:10.2217/nnm.14.38
Chemical modification of the 6'‐amino cyclopropyl of abacavir eliminates HLA‐B*57:01‐restricted CD8+ T‐cell activation without loss of antiviral activity
Alhaidari, M., Yang, E., Berry, N., Owen, A., Clarke, S., O'Neill, P., . . . Park, K. (2014). Chemical modification of the 6'‐amino cyclopropyl of abacavir eliminates HLA‐B*57:01‐restricted CD8+ T‐cell activation without loss of antiviral activity. Clinical and Translational Allergy, 4(S3). doi:10.1186/2045-7022-4-s3-p40
The application of nanotechnology in medicine: treatment and diagnostics
Owen, A., Dufes, C., Moscatelli, D., Mayes, E., Lovell, J. F., Katti, K. V., . . . Stone, V. (2014). The application of nanotechnology in medicine: treatment and diagnostics. NANOMEDICINE, 9(9), 1291-1294. doi:10.2217/NNM.14.93
Enabling the genomic revolution in Africa
Rotimi, C. (2014). Enabling the genomic revolution in Africa. SCIENCE, 344(6190), 1346-1348. doi:10.1126/science.1251546
Polydendrons
Rannard, S., Owen, A., Rogers, H., Hatton, F., & Southworth, F. (2014, June 13). WO2014199175 A1, Polydendrons.
Is methanol really a bad solvent for poly(<i>n</i>-butyl methacrylate)? Low dispersity and high molecular weight polymers of <i>n</i>-butyl methacrylate synthesised <i>via</i> ATRP in anhydrous methanol
Dwyer, A. B., Chambon, P., Town, A., He, T., Owen, A., & Rannard, S. P. (2014). Is methanol really a bad solvent for poly(<i>n</i>-butyl methacrylate)? Low dispersity and high molecular weight polymers of <i>n</i>-butyl methacrylate synthesised <i>via</i> ATRP in anhydrous methanol. POLYMER CHEMISTRY, 5(11), 3608-3616. doi:10.1039/c4py00182f
Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents
Hatton, F. L., Chambon, P., McDonald, T. O., Owen, A., & Rannard, S. P. (2014). Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents. CHEMICAL SCIENCE, 5(5), 1844-1853. doi:10.1039/c4sc00360h
Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2014). Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling. Poster session presented at the meeting of Conference On Retroviruses And Opportunistic Infections. Boston, MA, USA.
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(2), 491-499. doi:10.1093/jac/dkt372
The importance of HIV RNA detection below 50 copies per mL in HIV-positive patients on antiretroviral therapy: an observational study
Doyle, T., Smith, C., Vitiello, P., Cambiano, V., Johnson, M., Owen, A., . . . Geretti, A. M. (2014). The importance of HIV RNA detection below 50 copies per mL in HIV-positive patients on antiretroviral therapy: an observational study. LANCET, 383, 44. Retrieved from https://www.webofscience.com/
<i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073
<i>In vitro</i> characterization of efavirenz-containing solid drug nanoparticles
King, S. C., Oliveira, M., Moisi, D., Brenner, B., Giardiello, M., Rannard, S. P., . . . Geretti, A. M. (2014). <i>In vitro</i> characterization of efavirenz-containing solid drug nanoparticles. In ANTIVIRAL THERAPY Vol. 19 (pp. A126). Retrieved from https://www.webofscience.com/
CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.. Ther Drug Monit..
Conference Scene: Nanomedicine 2014, Edinburgh, UK, 26-27 March 2014
Owen, A., Dufès, C., Moscatelli, D., Mayes, E., Lovell, J. F., Katti, K. V., . . . Stone, V. (2014). Conference Scene: Nanomedicine 2014, Edinburgh, UK, 26-27 March 2014. Nanomedicine.
Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy
McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2014). Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy. HIV MEDICINE, 15, 53-54. Retrieved from https://www.webofscience.com/
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions
Liptrott, N., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2014). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine (London).
Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine
Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.
Investigating the interaction of gold nanoparticles with the human immune system
Kendall, E., Liptrott, N., & Owen, A. (2014). Investigating the interaction of gold nanoparticles with the human immune system. SCOTTISH MEDICAL JOURNAL, 59(1), E34. Retrieved from https://www.webofscience.com/
Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration
Moss, D., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents
Boffito, M., Jackson, A., Owen, A., & Becker, S. (2014). New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. DRUGS, 74(1), 7-13. doi:10.1007/s40265-013-0163-7
Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. Nanomedicine (London).
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.. J Antimicrob Chemother., 69(2), 491-499.
Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir
Alvarez, E., Owen, A., Martin Carbonero, L., Siccardi, M., Valencia, E., Moreno, V., . . . Rodriguez-Novoa, S. (2014). Polymorphisms in <i>SLC34A1</i> and <i>ABCC2</i> genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir. In ANTIVIRAL THERAPY Vol. 19 (pp. A11). Retrieved from https://www.webofscience.com/
Special issue of BJP on Nanomedicine
Owen, A. (2014). Special issue of BJP on Nanomedicine. BRITISH JOURNAL OF PHARMACOLOGY, 171(17), 3961-3962. doi:10.1111/bph.12820
Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs
Owen, A., & Curley, P. (2014). Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs. In Humanized Mice for HIV Research (pp. 339-360). Springer New York. doi:10.1007/978-1-4939-1655-9_28
The application of nanotechnology to drug delivery in Medicine
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Owen, A., & Rannard, S. (2014). The application of nanotechnology to drug delivery in Medicine. In P. Dolez (Ed.), Nano Engineering: Global Approaches to Health and Safety Issues (pp. 1-500). Toronto: Elsevier Health Sciences.
The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents
Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
The role of drug transporters in the kidney: lessons from tenofovir
Moss, D. M., Neary, M., & Owen, A. (2014). The role of drug transporters in the kidney: lessons from tenofovir. FRONTIERS IN PHARMACOLOGY, 5. doi:10.3389/fphar.2014.00248
2013
Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine
Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J., & Owen, A. (2013). Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 6366-6369. doi:10.1128/AAC.01124-13
Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13
Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA
Williamson, B., Soars, A. C., Owen, A., White, P., Riley, R. J., & Soars, M. G. (2013). Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. XENOBIOTICA, 43(10), 920-931. doi:10.3109/00498254.2013.776194
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i>
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against <i>Escherichia coli</i>. JOURNAL OF MATERIALS CHEMISTRY B, 1(35), 4455-4465. doi:10.1039/c3tb20543f
Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67
Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
Geretti, A. M., Fox, Z., Johnson, J. A., Booth, C., Lipscomb, J., Stuyver, L. J., . . . Phillips, A. (2013). Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. PLOS ONE, 8(7). doi:10.1371/journal.pone.0069266
Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 52(7), 613-614. doi:10.1007/s40262-013-0066-5
Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients
Martin, P., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2013). Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients. MOLECULAR PHARMACEUTICS, 10(7), 2739-2748. doi:10.1021/mp400175n
Predicting intestinal absorption of raltegravir using a population-based ADME simulation
Moss, D. M., Siccardi, M., Back, D. J., & Owen, A. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(7), 1627-1634. doi:10.1093/jac/dkt084
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7
Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients
Molto, J., Xinarianos, G., Miranda, C., Pushpakom, S., Cedeno, S., Clotet, B., . . . Valle, M. (2013). Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients. CLINICAL PHARMACOKINETICS, 52(7), 543-553. doi:10.1007/s40262-013-0057-6
ABCB1 single nucleotide polymorphisms (1236C > T, 2677G > T, and 3435C > T) do not affect transport activity of human P-glycoprotein
Dickens, D., Owen, A., Alfirevic, A., & Pirmohamed, M. (2013). ABCB1 single nucleotide polymorphisms (1236C > T, 2677G > T, and 3435C > T) do not affect transport activity of human P-glycoprotein. PHARMACOGENETICS AND GENOMICS, 23(6), 314-323. doi:10.1097/FPC.0b013e328360d10c
Transport of gabapentin by LAT1 (SLC7A5)
Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Raedisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). BIOCHEMICAL PHARMACOLOGY, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022
Transport of gabapentin by LAT1 (SLC7A5)
Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Rädisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). Biochemical Pharmacology, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022
A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp
Dickens, D., Yusof, S. R., Abbott, N. J., Weksler, B., Romero, I. A., Couraud, P. -O., . . . Owen, A. (2013). A Multi-System Approach Assessing the Interaction of Anticonvulsants with P-gp. PLOS ONE, 8(5). doi:10.1371/journal.pone.0064854
Compositions of Lopinavir and Ritonavir
Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., & Martin, P. (2013). Compositions of Lopinavir and Ritonavir.
HIV Drug Nanodispersions
Rannard, S., Owen, A., Giardiello, M., McDonald, T., Smith, D., & Martin, P. (2013). HIV Drug Nanodispersions.
Nanoparticles Formulation of Lopinavir
Rannard, S., Owen, A., Smith, S., Giardiello, M., McDonald, T., Martin, P., & Long, J. (2013). Nanoparticles Formulation of Lopinavir.
Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor
Cortes, C. P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G., & la Porte, C. J. L. (2013). Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. THERAPEUTIC DRUG MONITORING, 35(1), 78-83. doi:10.1097/FTD.0b013e318274197e
<i>RXR</i> gene variants are associated with HIV lipodystrophy
Pushpakom, S. P., Owen, A., Back, D. J., & Pirmohamed, M. (2013). <i>RXR</i> gene variants are associated with HIV lipodystrophy. PHARMACOGENETICS AND GENOMICS, 23(8), 438-441. doi:10.1097/FPC.0b013e328362cfc6
'Research Spotlight: Nanomedicines for HIV therapy'
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). 'Research Spotlight: Nanomedicines for HIV therapy'. Therapeutic Delivery, 4(2), 153.
A multi-system approach assessing the interaction of anticonvulsants with P-gp.
Dickens, D., Yusof, S. R., Abbott, N. J., Weksler, B., Romero, I. A., Couraud, P. -O., . . . Owen, A. (2013). A multi-system approach assessing the interaction of anticonvulsants with P-gp.. PloS One, 8(5), e64854.
Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles
Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
HIV-1 DNA decline during long-term first-line NNRTI-based ART with consistent plasma HIV-1 RNA suppression below 50 copies/ml
Geretti, A. M., Cozzi-Lepri, A., Vitiello, P., King, S., Owen, A., & Phillips, A. (2013). HIV-1 DNA decline during long-term first-line NNRTI-based ART with consistent plasma HIV-1 RNA suppression below 50 copies/ml. In ANTIVIRAL THERAPY Vol. 18 (pp. A27). Retrieved from https://www.webofscience.com/
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. Journal of Materials Chemistry B, 1(35), 4455. doi:10.1039/c3tb20543f
Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach
Curley, P., Schipani, A., Siccardi, M., & Owen, A. (2013). Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach. Poster session presented at the meeting of Manchester Life Sciences PhD Conference. Manchester, UK.
Nanomedicines for HIV therapy.
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV therapy.. Therapeutic delivery, 4(2), 153-156. doi:10.4155/tde.12.156
Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching
Giardiello, M., McDonald, T. O., Lee, J. -S., Roberts, A. D., Owen, A., & Rannard, S. P. (2013). Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching. GREEN CHEMISTRY, 15(6), 1590-1599. doi:10.1039/c3gc40573g
Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies
Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.
Siccardi, M., Olagunju, A., Seden, K., Ebrahimjee, F., Rannard, S., Back, D., & Owen, A. (2013). Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.. In silico pharmacology, 1, 4. doi:10.1186/2193-9616-1-4
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles
Giardiello, M., McDonald, T. O., Martin, P., Owen, A., & Rannard, S. P. (2012). Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles. JOURNAL OF MATERIALS CHEMISTRY, 22(47), 24744-24752. doi:10.1039/c2jm34974d
Regulation of <i>CYP3A4</i> and <i>CYP3A5</i> expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor
Maguire, O., Pollock, C., Martin, P., Owen, A., Smyth, T., Doherty, D., . . . Thompson, P. (2012). Regulation of <i>CYP3A4</i> and <i>CYP3A5</i> expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 364(1-2), 54-64. doi:10.1016/j.mce.2012.08.007
Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2012). Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 60. doi:10.7448/IAS.15.6.18339
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an <i>In Vitro</i>-<i>In Vivo</i> Extrapolation Model. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(4), 494-502. doi:10.1038/clpt.2012.61
Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding
Olagunju, A., Owen, A., & Creesey, T. R. (2012). Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. PHARMACOGENOMICS, 13(13), 1501-1522. doi:10.2217/PGS.12.138
Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095
Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems
McDonald, T. O., Martin, P., Patterson, J. P., Smith, D., Giardiello, M., Marcello, M., . . . Rannard, S. (2012). Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. ADVANCED FUNCTIONAL MATERIALS, 22(12), 2469-2478. doi:10.1002/adfm.201103059
Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11
\Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals
Arab-Alameddine, M., Fayet-Mello, A., Lubomirov, R., Neely, M., di Iulio, J., Owen, A., . . . Csajka, C. (2012). \Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 2959-2966. doi:10.1128/AAC.05424-11
Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
Siccardi, M., D'Avolio, A., Rodriguez-Novoa, S., Cuenca, L., Simiele, M., Baietto, L., . . . Di Perri, G. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. THERAPEUTIC DRUG MONITORING, 34(2), 232-235. doi:10.1097/FTD.0b013e31824aa50a
Lamotrigine is a substrate for OCT1 in brain endothelial cells
Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. BIOCHEMICAL PHARMACOLOGY, 83(6), 805-814. doi:10.1016/j.bcp.2011.12.032
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. Journal of Antimicrobial Chemotherapy, 67(3), 675-680. doi:10.1093/jac/dkr491
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies
Taylor, S., Jayasuriya, A., Fisher, M., Allan, S., Wilkins, E., Gilleran, G., . . . Smit, E. (2012). Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 675-680. doi:10.1093/jac/dkr491
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 671-674. doi:10.1093/jac/dkr493
Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy
Doyle, T., Smith, C., Vitiello, P., Cambiano, V., Johnson, M., Owen, A., . . . Geretti, A. M. (2012). Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES, 54(5), 724-732. doi:10.1093/cid/cir936
Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82e
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults
Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.
Investigation of the potential interactions of efavirenz with the GABAa receptor
Curley, P., Schipani, A., Egan, D., Siccardi, M., Wyen, C., Fätkenheuer, G., & Owen, A. (2012). Investigation of the potential interactions of efavirenz with the GABAa receptor. Poster session presented at the meeting of British Pharmacology Society Winter Meeting. London, UK.
Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.. Journal of Antimicrobial Chemotherapy, 67, 671-674.
PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Edwards, D., . . . Back, D. (2012). PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF EFAVIRENZ DOSE REDUCTION USING A PHYSIOLOGICALLY-BASED DYNAMIC MODEL. CLINICAL PHARMACOLOGY & THERAPEUTICS, 91, S104. Retrieved from https://www.webofscience.com/
Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV positive and Healthy Individuals
Arab-Alameddine, M., Fayet-Mello, A., Lubomirov, R., Neely, M., di Iulio, J., Boffito, M., . . . Csajka, C. (2012). Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 56, 2959-2966.
Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation
Rannard, S. P., McDonald, T. O., Owen, A., Giardiello, M., Martin, P., & Liptrot, N. (2012). Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 244. Retrieved from https://www.webofscience.com/
Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation
Rannard, S. P., McDonald, T. O., Owen, A., Giardiello, M., Martin, P., & Liptrot, N. (2012). Rapid "bottom-up" production of organic nanoparticles: From drug bioavailability enhancement to fluorescence studies of cellular accumulation. In 244th ACS National Meeting & Exposition (pp. COLL-196). Philadelphia: ACS.
2011
IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients
Liptrott, N. J., Egan, D., Back, D. J., & Owen, A. (2011). IFN-γ 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 442-445. doi:10.1097/QAI.0b013e318236441c
Current Progress in the Pharmacogenetics of Infectious Disease Therapy
Mahungu, T., & Owen, A. (2011). Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In GENETICS AND EVOLUTION OF INFECTIOUS DISEASES (pp. 555-578). doi:10.1016/B978-0-12-384890-1.00020-0
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10(1). doi:10.1186/1476-4598-10-37
Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., . . . Owen, A. (2011). Cytochrome P450 2B6 (<i>CYP2B6</i>) and constitutive androstane receptor (<i>CAR</i>) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(9), 2092-2098. doi:10.1093/jac/dkr272
The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
Chigutsa, E., Visser, M. E., Swart, E. C., Denti, P., Pushpakom, S., Egan, D., . . . McIlleron, H. (2011). The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(9), 4122-4127. doi:10.1128/AAC.01833-10
Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein
Vogler, M., Dickens, D., Dyer, M. J. S., Owen, A., Pirmohamed, M., & Cohen, G. M. (2011). The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 408(2), 344-349. doi:10.1016/j.bbrc.2011.04.043
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. MOLECULAR CANCER, 10. doi:10.1186/1476-4598-10-37
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism (vol 62, pg 1188, 2008)
Garcia-Diaz, A., Lok, C. B., Madge, S., Booth, C., Tyrer, M., Bonora, S., . . . Geretti, A. M. (2011). Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism (vol 62, pg 1188, 2008). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(3), 688. doi:10.1093/jac/dkq534
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 7(3), 341-352. doi:10.1517/17425255.2011.553600
Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort
Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800
Sequence and gene expression of chloroquine resistance transporter (<i>pfcrt</i>) in the association of <i>in vitro</i> drugs resistance of <i>Plasmodium falciparum</i>
Chaijaroenkul, W., Ward, S. A., Mungthin, M., Johnson, D., Owen, A., Bray, P. G., & Na-Bangchang, K. (2011). Sequence and gene expression of chloroquine resistance transporter (<i>pfcrt</i>) in the association of <i>in vitro</i> drugs resistance of <i>Plasmodium falciparum</i>. MALARIA JOURNAL, 10. doi:10.1186/1475-2875-10-42
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10
20 Current Progress in the Pharmacogenetics of Infectious Disease Therapy
Mahungu, T., & Owen, A. (2011). 20 Current Progress in the Pharmacogenetics of Infectious Disease Therapy. In Genetics and Evolution of Infectious Disease (pp. 555-578). Elsevier. doi:10.1016/b978-0-12-384890-1.00020-0
Adipogenic gene variants in patients with HIV-associated lipodystrophy
Pushpakom, S. P., Owen, A., Vilar, F. J., Castro, H., Dunn, D. T., Back, D. J., & Pirmohamed, M. (2011). Adipogenic gene variants in patients with HIV-associated lipodystrophy. PHARMACOGENETICS AND GENOMICS, 21(2), 76-83. doi:10.1097/FPC.0b013e328342a917
Compositions of Lopinavir & Ritonavir
Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., & Martin, P. (2011). Compositions of Lopinavir & Ritonavir.
HIV Drug Nanodispersions
Rannard, S., Owen, A., McDonald, T., Smith, D., Giardiello, M., & Martin, P. (2011). HIV Drug Nanodispersions.
Highly Active Antiretroviral Nanoparticles: High Throughout Particle Synthesis, Toxicology and Efficacy Studies
McDonald, T. O., Giardielo, M., Smith, D., Martin, P., Owen, A., & Rannard, S. P. (2011). Highly Active Antiretroviral Nanoparticles: High Throughout Particle Synthesis, Toxicology and Efficacy Studies. In 2nd Nano Today Conference (pp. 1). Waikoloa: Nano Today.
Multi-Component Organic Nanoparticles forMagnetic and Fluorescent Studies in Biological Systems
McDonald, T., Martin, P., Giardiello, M., Smith, D., Owen, A., & Rannard, S. (2011). Multi-Component Organic Nanoparticles forMagnetic and Fluorescent Studies in Biological Systems. In Nano Today (pp. 1). Waikoloa: Nano Today.
Nanoparticles Formulation of Lopinavir
Rannard, S., Owen, A., Smith, D., Giardiello, M., McDonald, T., Martin, P., & Long, J. (2011). Nanoparticles Formulation of Lopinavir.
Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is over-expressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 10, 37.
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications
Chigutsa, E., Visser, M. E., Swart, E. C., Denti, P., Pushpakom, S., Egan, D., . . . McIlleron, H. (2011). The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications. Antimicrob Agents Chemother, 55(9), 4122-4127.
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. Expert Opinion on Drug Metabolism and Toxicology.
2010
Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 <i>in vitro</i> and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. PHARMACOGENETICS AND GENOMICS, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efb
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10
Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV‐infected patients
Zhang, Y., Owen, A., Egan, D., & Sarfo, S. F. (2010). Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV‐infected patients. Journal of the International AIDS Society, 13(S4). doi:10.1186/1758-2652-13-s4-p183
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., Back, D. J., . . . Owen, A. (2010). SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients. Journal of the International AIDS Society, 13, P178. doi:10.1186/1758-2652-13-s4-p178
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort
Carr, D. F., la Porte, C. J. L., Pirmohamed, M., Owen, A., & Cortes, C. P. (2010). Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(9), 1889-1893. doi:10.1093/jac/dkq260
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms
Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02d
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02d
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells
Martin, P., Riley, R., Thompson, P., Williams, D., Back, D., & Owen, A. (2010). Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. ACTA PHARMACOLOGICA SINICA, 31(1), 51-65. doi:10.1038/aps.2009.187
Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2
Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.
The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2010). The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. BRITISH JOURNAL OF PHARMACOLOGY, 159(2), 484-493. doi:10.1111/j.1476-5381.2009.00552.x
2009
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes
Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(5), 1002-1007. doi:10.1093/jac/dkp335
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.
Nanomedicine: Not a case of "One size fits all"
Rannard, S., & Owen, A. (2009). Nanomedicine: Not a case of "One size fits all". NANO TODAY, 4(5), 382-384. doi:10.1016/j.nantod.2009.07.002
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.x
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC
Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz
Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. CLINICAL PHARMACOLOGY & THERAPEUTICS, 86(2), 204-211. doi:10.1038/clpt.2009.78
Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. CLINICAL INFECTIOUS DISEASES, 48(11), E108-E116. doi:10.1086/598507
Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives
Vandekerckhove, L. P. R., Christ, F., Debyser, Z., Owen, A., Back, D., Voet, A., . . . Vogelaers, D. (2009). Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives. In ANTIVIRAL RESEARCH: STRATEGIES IN ANTIVIRAL DRUG DISCOVERY (pp. 71-+). Retrieved from https://www.webofscience.com/
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV MEDICINE, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.x
<i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa
Alker, A. P., Juliano, J. J., & Meshnick, S. R. (2009). <i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(4), 1722. doi:10.1128/AAC.01427-08
The impact of pharmacogenetics on HIV therapy
Mahungu, T. W., Johnson, M. A., Owen, A., & Back, D. J. (2009). The impact of pharmacogenetics on HIV therapy. INTERNATIONAL JOURNAL OF STD & AIDS, 20(3), 145-151. doi:10.1258/ijsa.2008.008369
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study
Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.
2008
Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry
Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism
Garcia-Diaz, A., Blok, C., Madge, S., Booth, C., Tyrer, M., Bonora, S., . . . Geretti, A. M. (2008). Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the <i>CYP2B6</i> 516 TT polymorphism. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1188-1190. doi:10.1093/jac/dkn374
<i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure
Ochong, E., Bell, D. J., Johnson, D. J., D'Alessandro, U., Mulenga, M., Muangnoicharoen, S., . . . Owen, A. (2008). <i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 3883-3888. doi:10.1128/AAC.00431-08
Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir
Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304
Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir
Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. BRITISH JOURNAL OF PHARMACOLOGY, 155(6), 875-883. doi:10.1038/bjp.2008.320
Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial<i>bc</i><sub>1</sub>Complex
Biagini, G. A., Fisher, N., Berry, N., Stocks, P. A., Meunier, B., Williams, D. P., . . . Ward, S. A. (2008). Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial<i>bc</i><sub>1</sub>Complex. Molecular Pharmacology, 73(5), 1347-1355. doi:10.1124/mol.108.045120
Acridinediones:: Selective and potent inhibitors of the malaria parasite mitochondrial <i>bc</i><sub>1</sub> complex
Biagini, G. A., Fisher, N., Berry, N., Stocks, P. A., Meunier, B., Williams, D. P., . . . Ward, S. A. (2008). Acridinediones:: Selective and potent inhibitors of the malaria parasite mitochondrial <i>bc</i><sub>1</sub> complex. MOLECULAR PHARMACOLOGY, 73(5), 1347-1355. doi:10.1124/mol.108.045120
Pharmacogenetics of antiretroviral agents
Owen, A., & Khoo, S. H. (2008). Pharmacogenetics of antiretroviral agents. CURRENT OPINION IN HIV AND AIDS, 3(3), 288-295. doi:10.1097/COH.0b013e3282f7cda4
Drug-regulated expression of <i>Plasmodium falciparum</i> P-glycoprotein hornologue 1:: a putative role for nuclear receptors
Johnson, D. J., Owen, A., Plant, N., Bray, P. G., & Ward, S. A. (2008). Drug-regulated expression of <i>Plasmodium falciparum</i> P-glycoprotein hornologue 1:: a putative role for nuclear receptors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(4), 1438-1445. doi:10.1128/AAC.01392-07
Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . Owen, A. (2008). Impact of <i>CYP2B6</i> 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 914-918. doi:10.1093/jac/dkn029
Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells
Martin, P., Riley, R., Back, D. J., & Owen, A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. BRITISH JOURNAL OF PHARMACOLOGY, 153(4), 805-819. doi:10.1038/sj.bjp.0707601
Acridinediones:: a new class of potent inhibitors selective against the mitochondrial bc1 complex of the malaria parasite <i>Plasmodium falciparum</i>.
Biagini, G. A., Fisher, N., Berry, N., Stocks, P., Meunier, B., Bray, P. G., . . . Ward, S. A. (2008). Acridinediones:: a new class of potent inhibitors selective against the mitochondrial bc1 complex of the malaria parasite <i>Plasmodium falciparum</i>.. In INTERNATIONAL JOURNAL FOR PARASITOLOGY Vol. 38 (pp. S41). Retrieved from https://www.webofscience.com/
Drug-regulated gene expression of <i>Plasmodium falciparum</i> P-glycoprotein homologue 1:: a role for nuclear receptors?
Johnson, D. J., Owen, A., Plant, N., & Ward, S. A. (2008). Drug-regulated gene expression of <i>Plasmodium falciparum</i> P-glycoprotein homologue 1:: a role for nuclear receptors?. In INTERNATIONAL JOURNAL FOR PARASITOLOGY Vol. 38 (pp. S39). Retrieved from https://www.webofscience.com/
Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs
Chaikan, A., Chierakul, N., Saguenwong, N., Chuchuttaworn, C., Owen, A., Dickinson, L., . . . Davies, G. R. (2008). Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs. In Journal of the International AIDS Society Vol. 11 (pp. P237). Wiley. doi:10.1186/1758-2652-11-s1-p237
Lopinavir is a substrate for SLCO1A2 but 516A>C and 38T>C polymorphisms do not influence lopinavir plasma concentrations
Shallcross, V., Kwan, W. S., Hartkoorn, R., Mahungu, T., Khoo, S. H., Back, D. J., & Owen, A. (2008). Lopinavir is a substrate for SLCO1A2 but 516A>C and 38T>C polymorphisms do not influence lopinavir plasma concentrations. Journal of the International AIDS Society, 11(Suppl 1), P238. doi:10.1186/1758-2652-11-s1-p238
O122 Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi teaching and referral hospital (Ampath), Eldoret, Kenya
Kigen, G. K., Kimaiyo, S., Back, D. J., Gibbons, S. E., Sang, E., Edwards, I. G., . . . Khoo, S. H. (2008). O122 Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi teaching and referral hospital (Ampath), Eldoret, Kenya. Journal of the International AIDS Society, 11(Suppl 1), O7. doi:10.1186/1758-2652-11-s1-o7
Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C>T SNP in the PXR gene
Siccardi, M., D'Avolio, A., Baietto, L., Calcagno, A., Gibbons, S. E., Sciandra, M., . . . Owen, A. (2008). Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C>T SNP in the PXR gene. Journal of the International AIDS Society, 11(Suppl 1), P233. doi:10.1186/1758-2652-11-s1-p233
TRANSCRIPTIONAL ANALYSIS OF PUTATIVE FOLATE TRANSPORTER GENES IN <i>PLASMODIUM FALCIPARUM</i>
Ochong, E., Salcedo, E., Bray, P., Ward, S., & Owen, A. (2008). TRANSCRIPTIONAL ANALYSIS OF PUTATIVE FOLATE TRANSPORTER GENES IN <i>PLASMODIUM FALCIPARUM</i>. In AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Vol. 79 (pp. 302). Retrieved from https://www.webofscience.com/
2007
Tacrine-induced liver damage: an analysis of 19 candidate genes
Alfirevic, A., Mills, T., Carr, D., Barratt, B. J., Jawaid, A., Sherwood, J., . . . Pirmohamed, M. (2007). Tacrine-induced liver damage: an analysis of 19 candidate genes. PHARMACOGENETICS AND GENOMICS, 17(12), 1091-1100. doi:10.1097/FPC.0b013e3282f1f12b
Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes
Janneh, O., Jones, E., Chandler, B., Owen, A., & Khoo, S. H. (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(5), 987-993. doi:10.1093/jac/dkm353
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification
Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(4), 881-884. doi:10.1093/jac/dkm281
Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects
Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(3), 685-689. doi:10.1093/jac/dkm230
Detection and biochemical characterisation of a novel polymorphism in the human <i>GSTP1</i> gene
Kitteringham, N. R., Palmer, L., Owen, A., Lian, L. -Y., Jenkins, R., Dowdall, S., . . . Goldring, C. E. (2007). Detection and biochemical characterisation of a novel polymorphism in the human <i>GSTP1</i> gene. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1770(8), 1240-1247. doi:10.1016/j.bbagen.2007.05.001
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein
Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. TUBERCULOSIS, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001
Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>
Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>. ANTIVIRAL THERAPY, 12(5), 831-834. Retrieved from https://www.webofscience.com/
Influence of PD1 Genotype on Virological and Immunological Response in Patients Initiating ART
Liptrott, N., Mahungu, T., Youle, M., Johnson, M., Smith, C., Back, D., . . . Owen, A. (2007). Influence of PD1 Genotype on Virological and Immunological Response in Patients Initiating ART. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 452. Retrieved from http://www.retroconference.org/2007/Abstracts/29534.htm
TB Drug Tolerance: Differential Drug Susceptibility of Intracellular and Extracellular TB and the Effect of Time of Drug Exposure
Hartkoorn, R., Chandler, B., Owen, A., Ward, S., Squire, B., Back, D., & Khoo, S. (2007). TB Drug Tolerance: Differential Drug Susceptibility of Intracellular and Extracellular TB and the Effect of Time of Drug Exposure. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 854. Retrieved from http://www.retroconference.org/2007/Abstracts/28849.htm
The Assessment of Multi-locus Gene Effects upon Efavirenz Pharmacokinetics
Mahungu, T., Khoo, S., Smith, C., Youle, M., Johnson, M., Back, D., & Owen, A. (2007). The Assessment of Multi-locus Gene Effects upon Efavirenz Pharmacokinetics. 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February, Los Angeles, CA, USA, N/A, Abstract 552. Retrieved from http://www.retroconference.org/2007/Abstracts/28960.htm
2006
Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug
Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. ANNALS OF THE RHEUMATIC DISEASES, 65(10), 1390-1393. doi:10.1136/ard.2005.049189
Pharmacogenetics of HIV therapy
Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. PHARMACOGENETICS AND GENOMICS, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57
The impact of host pharmacogenetics on antiretroviral drug disposition.
Owen, A. (2006). The impact of host pharmacogenetics on antiretroviral drug disposition.. Current infectious disease reports, 8(5), 401-408. doi:10.1007/s11908-006-0052-2
Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements
Owen, A., Goldring, C., Morgan, P., Park, B. K., & Pirmohamed, M. (2006). Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 62(2), 237-242. doi:10.1111/j.1365-2125.2006.02587.x
Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance
Leschziner, G., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A. J., . . . Johnson, M. R. (2006). Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. PHARMACOGENETICS AND GENOMICS, 16(6), 439-450. doi:10.1097/01.fpc.0000197467.21964.67
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals
Back, D. J., Owen, A., & Khoo, S. H. (2006). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. CLINICAL PHARMACOKINETICS, 45(2), 213-214. doi:10.2165/00003088-200645020-00006
Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes
Goldring, C. E. P., Kitteringham, N. R., Jenkins, R., Lovatt, C. A., Randle, L. E., Abdullah, A., . . . Park, B. K. (2006). Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 290(1), C104-C115. doi:10.1152/ajpcell.00133.2005
Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance
Leschziner, G. D., Zabaneh, D., Pirmohamed, M., Owen, A., Rogers, J., Coffey, A. J., . . . Johnson, M. R. (2006). Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenetics and Genomics, 16(6), 439-450.
Induction of ART-relevant Drug Transporters and Metabolism Enzymes in Intestinal and Hepatic Cells by Rifampicin
Martin, P., Riley, R., Khoo, S., Back, D., & Owen, A. (2006). Induction of ART-relevant Drug Transporters and Metabolism Enzymes in Intestinal and Hepatic Cells by Rifampicin. 13th Conference on Retroviruses and Opportunistic Infections, N/A(5-8 Fe), Abstract 567.
Relationship of G516T Polymorphism to Lymphocyte Expression of CYP2B6
Owen, A., Cook, C., Liptrott, N., Khoo, S., & Back, D. (2006). Relationship of G516T Polymorphism to Lymphocyte Expression of CYP2B6. 13th Conference on Retroviruses and Opportunistic Infections, N/A(5-8 Fe), Abstract 765.
The assessment of multi-locus gene effects upon lopinavir pharmacokinetics
Owen, A., Mahungu, T., Cook, C., Youle, M., Johnson, M., Back, D., & Khoo, S. (2006). The assessment of multi-locus gene effects upon lopinavir pharmacokinetics. Eighth International Congress on Drug Therapy in HIV Infection, November, Glasgow, UK., N/A, Abstract PL5.4.
2005
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.. The Journal of pharmacology and experimental therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272
The implications of P-glycoprotein in HIV: friend or foe?
Owen, A., Chandler, B., & Back, D. J. (2005). The implications of P-glycoprotein in HIV: friend or foe?. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 19(3), 283-296. doi:10.1111/j.1472-8206.2005.00324.x
Relationship between the C<sub>3435</sub>T and G<sub>2677</sub>T(A) polymorphisms in the <i>ABCB1</i> gene and P-glycoprotein expression in human liver
Owen, A., Goldring, C., Morgan, P., Chadwick, D., Park, B. K., & Pirmohamed, M. (2005). Relationship between the C<sub>3435</sub>T and G<sub>2677</sub>T(A) polymorphisms in the <i>ABCB1</i> gene and P-glycoprotein expression in human liver. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 59(3), 365-370. doi:10.1111/j.1365-2125.2005.02229.x
Correlation between P-glycorotein and CXCR4 on PBMC and CD4+ cells isolated from HIV+ individuals
Chandler, B., Khoo, S., Detsika, M., Walsh, T., Williams, J., Back, D., & Owen, A. (2005). Correlation between P-glycorotein and CXCR4 on PBMC and CD4+ cells isolated from HIV+ individuals. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 665.
Host determinants of antiretroviral drug activity
Boffito, M., Alan, W., & Owen, A. (2005). Host determinants of antiretroviral drug activity. CURRENT OPINION IN INFECTIOUS DISEASES, 18(6), 543-549. doi:10.1097/01.qco.0000191507.48481.10
In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine
Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.
Induction of intestinal and hepatic disposition genes by paradigm nuclear receptor ligands: comparison between rodent and human intestinal and hepatic cell lines
Martin, P., Owen, A., Back, D., & Riley, R. (2005). Induction of intestinal and hepatic disposition genes by paradigm nuclear receptor ligands: comparison between rodent and human intestinal and hepatic cell lines. DMDG Open Meeting, N/A(7-9 Se), N/A.
Interindividual variation in the expression of the cellular redox sensor Keap1 and its novel splice variants in human lymphocytes
Abdullah, A., Goldring, C., Owen, A., Kitteringham, N., & Park, K. (2005). Interindividual variation in the expression of the cellular redox sensor Keap1 and its novel splice variants in human lymphocytes. Toxicology, 213(3), 261-262.
Mitochondria are sensors for HIV drugs
Petit, F., Fromenty, B., Owen, A., & Estaquier, J. (2005). Mitochondria are sensors for HIV drugs. TRENDS IN PHARMACOLOGICAL SCIENCES, 26(5), 258-264. doi:10.1016/j.tips.2005.03.006
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16284458
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP
Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.
P-Glycoprotein and MRP1 Interactions with Rifampicin
Hartkoorn, R., Waitt, C., Chaponda, M., Davies, G., Chandler, B., Owen, A., . . . Khoo, S. (2005). P-Glycoprotein and MRP1 Interactions with Rifampicin. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 666.
Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype
Owen, A., Almond, L., Hartkoorn, R., Walsh, T., Youle, M., Bonington, A., . . . Khoo, S. (2005). Relevance of Drug Transporters and Drug Metabolism Enzymes to Nevirapine: Superimposition of Host Genotype. 12th Conference on Retroviruses and Opportunistic Infections, N/A(22-25), Abstract 650.
The Implications of P-glycoprotein: Friend or Foe?
Owen, A., Chandler, B., & Back, D. (2005). The Implications of P-glycoprotein: Friend or Foe?. Fundamentals of Clinical Pharmacology, 19, 238-296.
The impact of gender on saquinavir hard-gel/ritonavir (1000/100mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals
Dickinson, L., Back, D., Chandler, B., Owen, A., Khoo, S., Pozniak, A., & Boffito, M. (2005). The impact of gender on saquinavir hard-gel/ritonavir (1000/100mg bid) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. 6th International Workshop on Clinical Pharmacology of HIV Therapy, N/A(April), Abstract 9.
2004
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. JOURNAL OF VIROLOGY, 78(21), 12022-12029. doi:10.1128/JVI.78.21.12022-12029.2004
Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. ANTIVIRAL THERAPY, 9(5), 819-821. Retrieved from https://www.webofscience.com/
MULTI DRUG RESISTANCE PUMP (P-GLYCOPROTEIN) EXPRESSION IN PERIPHERAL BLOOD OF HEART TRANSPLANT RECIPIENTS IS NOT ASSOCIATED WITH REJECTION.
Thekkudan, J., Fildes, J., Guntamadugu, R., Owen, A., Walker, A., Datta, S., . . . Leonard, C. (2004). MULTI DRUG RESISTANCE PUMP (P-GLYCOPROTEIN) EXPRESSION IN PERIPHERAL BLOOD OF HEART TRANSPLANT RECIPIENTS IS NOT ASSOCIATED WITH REJECTION.. Transplantation, 78, 426. doi:10.1097/00007890-200407271-01141
Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression
Singh, D., Alexander, J., Owen, A., Rustom, R., Bone, M., Hammad, A., . . . Pirmohamed, M. (2004). Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. TRANSPLANTATION, 77(4), 557-561. doi:10.1097/01.TP.0000114594.21317.A5
P-glycoprotein and outcome following lung transplantation
Fildes, J. E., Thekkudan, J., Guntamadugu, R., Owen, A., Singh, D., Yonan, N., & Leonard, C. T. (2004). P-glycoprotein and outcome following lung transplantation. The Journal of Heart and Lung Transplantation, 23(2), S166. doi:10.1016/j.healun.2003.11.370
-glycoprotein and outcome following lung transplantation
Fildes, J. E., Thekkudan, J., Guntamadugu, R., Owen, A., Singh, D., Yonan, N., & Leonard, C. T. (2004). -glycoprotein and outcome following lung transplantation. The International Society for Heart and Lung Transplantation 24th Annual Meeting and Scientific Sessions, N/A(21-24), N/A.
Co-expression and co-localisation of P-glycoprotein and CXCR4 in peripheral blood mononuclear cells
Chandler, B., Owen, A., Bray, P. G., Ward, S. A., Back, D. J., & Khoo, S. H. (2004). Co-expression and co-localisation of P-glycoprotein and CXCR4 in peripheral blood mononuclear cells. XV International AIDS Conference, N/A(11-18), N/A.
Correlation between transporters and HIV co-receptors in lymphocytes from HIV-infected patients: superimposition of host genotype
Owen, A., Chandler, B., Walsh, T., Williams, J., Penny, M., Back, D., & Khoo, S. (2004). Correlation between transporters and HIV co-receptors in lymphocytes from HIV-infected patients: superimposition of host genotype. Meeting on Pharmacogenomics, N/A(Novemb), 90.
Detection of Minority Strains of HIV Harbouring Drug Resistance
Detsika, M., Winstanley, C., Owen, A., Cane, P., Khoo, S., Back, D., & Hart, C. (2004). Detection of Minority Strains of HIV Harbouring Drug Resistance. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, N/A(30 Oct), N/A.
Development of doxycycline-regulatable gene expression in hepatoma cells
Goldring, C., Kitteringham, N., Lovatt, C., Jenkins, R., Randle, L., Abdullah, A., . . . Park, K. (2004). Development of doxycycline-regulatable gene expression in hepatoma cells. Joint meeting of the BPS/BTS. Adverse reactions to drugs and chemicals: studies from molecule to man, N/A(9-10 S), N/A.
Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype
Chandler, B., Owen, A., Back, D. J., & Khoo, S. H. (2004). Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype. 11th Conference on Retroviruses and Opportunistic Infections, N/A(8-11 F), N/A.
Drug efflux Transporters: Role in the Intracellular Accumulation and Activity of Antiretroviral Agents
Janneh, O., Owen, A., Hartkoorn, R. C., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Drug efflux Transporters: Role in the Intracellular Accumulation and Activity of Antiretroviral Agents. BSAC Spring Meeting 2004 in collaboration with the Society of Pharmaceutical Medicine, N/A(2-3 Ma), N/A.
Expression of Pregnane-X receptor transcripts in peripheral blood mononuclear cells and correlation with MDR1
Owen, A., Chandler, B., Back, D., & Khoo, S. H. (2004). Expression of Pregnane-X receptor transcripts in peripheral blood mononuclear cells and correlation with MDR1. Antiviral Therapy, 9(5), 819-821.
Expression of PXR transcript in lymphocytes and correlation with MDR1 mRNA: Implications for lymphocyte-acting drugs
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of PXR transcript in lymphocytes and correlation with MDR1 mRNA: Implications for lymphocyte-acting drugs. Microsomes and Drug Oxidations, N/A(4-9 Ju), N/A.
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4
Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.
In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein
Owen, A., Janneh, O., Bray, P. G., Hartkoorn, R. C., Baba, M., Ward, S. A., . . . Khoo, S. H. (2004). In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein. XV International AIDS Conference, N/A(11-18), N/A.
Interindividual variation in the expression of the redox sensor Keap1 and its novel splice variants in human lymphocytes
Abdullah, A., Goldring, C., Owen, A., Kitteringham, N., & Park, K. (2004). Interindividual variation in the expression of the redox sensor Keap1 and its novel splice variants in human lymphocytes. Adverse reactions to drugs and chemicals: studies from molecule to man, N/A(9-10 S), N/A.
Intracellular pharmacokinetics of antiretroviral agents.
Owen, A., & Khoo, S. H. (2004). Intracellular pharmacokinetics of antiretroviral agents.. Journal of HIV therapy, 9(4), 97-101.
Pharmacoenhancement of saquinavir by mefloquine via inhibition of multi-drug transporters
Owen, A., Janneh, O., Bray, P. G., Hartkoorn, R. C., Baba, M., Ward, S. A., . . . Khoo, S. H. (2004). Pharmacoenhancement of saquinavir by mefloquine via inhibition of multi-drug transporters. 2nd British Pharmacological Society Focused Meeting: Transporters and Drug Resistance, N/A(18-19), N/A.
The Role of Genetic Polymorphisms of the MDR1 (ABCB1) Gene in the MaxCmin1 Study
Owen, A., Fox, Z., Almond, L., Dragsted, U. B., Youle, M., Lundgren, J., . . . On behalf of the MaxCmin1 Steering Committee. (2004). The Role of Genetic Polymorphisms of the MDR1 (ABCB1) Gene in the MaxCmin1 Study. 11th Conference on Retroviruses and Opportunistic Infections, N/A(8-11 F), N/A.
The interaction between active drug transporters and rifampicin accumulation
Hartkoorn, R. C., Janneh, O., Owen, A., Davies, G. R., Chandler, R. J., Khoo, S., & Back, D. J. (2004). The interaction between active drug transporters and rifampicin accumulation. 2nd British Pharmacological Society Focused Meeting: Transporters and Drug Resistance, N/A(18-19), N/A.
2003
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines
Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/00002030-200310170-00024
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 33(5), 551-556. doi:10.1097/00126334-200308150-00001
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets
Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. JOURNAL OF IMMUNOLOGICAL METHODS, 274(1-2), 129-137. doi:10.1016/S0022-1759(02)00509-4
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells. JOURNAL OF INFECTIOUS DISEASES, 187(5), 874-875. doi:10.1086/367902
The mechanisms that control intracellular penetration of the HIV protease inhibitors
Hoggard, P. G., & Owen, A. (2003). The mechanisms that control intracellular penetration of the HIV protease inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 51(3), 493-496. doi:10.1093/jac/dkg137
A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets
Ford, J., Hoggard, P. G., & et, A. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods, 274(1-2), 129-137. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12609539
Differential expression of Human Immunodeficiency virus coreceptors by CEM, CEMVBL and CEME1000 cells.
Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of Human Immunodeficiency virus coreceptors by CEM, CEMVBL and CEME1000 cells.. Journal of Infectious Diseases, 18(5), 874-875.
Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype
Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2003). Does co-expression of P-glycoprotein and CXCR4 at the lymphocyte membrane determine viral replication and antiretroviral efficacy in vitro? Superimposition of host genotype. 1st meeting on pharmacogenomics and related applications of genomics, N/A(Septem), N/A.
Impact of ABCB1 (MDR1) haplotypes on human hepatic P-glycoprotein expression
Owen, A., Park, B. K., & Pirmohamed, M. (2003). Impact of ABCB1 (MDR1) haplotypes on human hepatic P-glycoprotein expression. 1st meeting on pharmacogenomics and related applications of genomics, N/A(Septem), N/A.
Mode of uptake, accumulation and intracellular disposition of zidovudine in cultured 3T3-F442A preadipocytes
Janneh, O., Owen, A., Bray, P. G., Back, D. J., & Pirmohamed, M. (2003). Mode of uptake, accumulation and intracellular disposition of zidovudine in cultured 3T3-F442A preadipocytes. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, N/A(July 8), N/A.
Modulation of intracellular saquinavir accumulation - Potential for augmenting anti-HIV effect
Owen, A., Janneh, O., Hartkoorn, R., Chandler, R., Back, D. J., & Khoo, S. H. (2003). Modulation of intracellular saquinavir accumulation - Potential for augmenting anti-HIV effect. Federation of Infection Societies Tenth Anniversary Conference, N/A(Novemb), N/A.
The Effect of ABCB1 (MDR1) Polymorphism on the Plasma and Intracellular Pharmacokinetics of Indinavir and Glucose Handling in Healthy Volunteers
Maher, B., Hoggard, P. G., Chandler, B., Meaden, E. R., Owen, A., Back, D. J., . . . Pirmohamed, M. (2003). The Effect of ABCB1 (MDR1) Polymorphism on the Plasma and Intracellular Pharmacokinetics of Indinavir and Glucose Handling in Healthy Volunteers. 10th Conference on Retroviruses and Opportunistic Infections, N/A(10-14), Abstract 524a.
The Relationship between P-glycoprotein and HIV-1 Co-Receptor Expression: Implications for antiretroviral disposition and viral dynamics.
Owen, A., Chandler, B., Khoo, S. H., & Back, D. J. (2003). The Relationship between P-glycoprotein and HIV-1 Co-Receptor Expression: Implications for antiretroviral disposition and viral dynamics.. 8th European ISSX meeting, N/A(Apr 27), Abstract 307.
The Relationship between P-glycoprotein and HIV-1 Receptors in Peripheral Blood Lymphocytes and Cell Lines.
Owen, A., Hoggard, P. G., Chandler, B., Khoo, S. H., & Back, D. J. (2003). The Relationship between P-glycoprotein and HIV-1 Receptors in Peripheral Blood Lymphocytes and Cell Lines.. 10th Conference on Retroviruses and Opportunistic Infections, N/A(10-14), Abstract 149.
The effects of protease inhibitors and non-nucleoside reverse transcripts inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro.
Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S. H., & Back., D. J. (2003). The effects of protease inhibitors and non-nucleoside reverse transcripts inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro.. Journal of Acquired Immune Deficiency Syndromes, 33(5), 551-556.
2002
Effect of efavirenz and nevirapine on P-gp expression: the impact on protease inhibitor fluxing
Almond, L. M., Chandler, B., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2002). Effect of efavirenz and nevirapine on P-gp expression: the impact on protease inhibitor fluxing. XIV International AIDS conference, N/A(7-12 J), N/A.
In-vitro Antiretroviral Activity of Antimalarial Agents.
Owen, A., Hoggard, P. G., Bray, P. G., Ward, S. A., Khoo, S. H., Hart, C. A., & Back, D. J. (2002). In-vitro Antiretroviral Activity of Antimalarial Agents.. Sixth International Congress on Drug Therapy in HIV Infection, N/A(17-21), N/A.
Induction of P-glycoprotein in PBMCs in vitro
Chandler, B., Ford, J., Owen, A., Khoo, S. H., & Back, D. J. (2002). Induction of P-glycoprotein in PBMCs in vitro. XIV International AIDS conference, N/A(7-12 J), N/A.
Lack of Correlation between C3435T Polymorphism in MDR1 and Hepatic P-glycoprotein Expression
Owen, A., Goldring, C., Morgan, P., Park, B. K., & Pirmohamed, M. (2002). Lack of Correlation between C3435T Polymorphism in MDR1 and Hepatic P-glycoprotein Expression. Proceedings of the British Pharmacological Society, N/A(12-14), N/A.
The role of drug transporters in HIV treatment failure
Owen, A., Hoggard, P. G., & Khoo, S. (2002). The role of drug transporters in HIV treatment failure. HIV and AIDS current trends, 8, 11-12.
2001
LC determination of carbamazepine in murine brain
Owen, A., Tettey, J. N., Morgan, P., Pirmohamed, M., & Park, B. K. (2001). LC determination of carbamazepine in murine brain. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 26(4), 573-577. doi:10.1016/S0731-7085(01)00477-0
Carbamazepine is not a substrate for P-glycoprotein
Owen, A., Pirmohamed, M., Tettey, J. N., Morgan, P., Chadwick, D., & Park, B. K. (2001). Carbamazepine is not a substrate for P-glycoprotein. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(4), 345-349. doi:10.1046/j.1365-2125.2001.01359.x
2000
Is Carbamazepine a Substrate for P-glycoprotein?
Owen, A., Pirmohamed, M., Tettey, J. N., Morgan, P., Chadwick, D., & Park, B. K. (2000). Is Carbamazepine a Substrate for P-glycoprotein?. Proceedings of the British Pharmacological Society, N/A(12-14), N/A.
Is carbamezapine a substrate for P-glycoprotein?
Owen, A., Pirmohamed, M., Tettey, J., Morgan, P., Chadwick, D., & Park, B. K. (2000). Is carbamezapine a substrate for P-glycoprotein?. In British Journal of Clinical Pharmacology Vol. 50 (pp. 387).
1999
Immunohistological Detection of P-glycoprotein in the Brain of Patients with Refractory Epilepsy
Owen, A., Pirmohamed, M., Morgan, P., Chadwick, D., & Park, B. K. (1999). Immunohistological Detection of P-glycoprotein in the Brain of Patients with Refractory Epilepsy. Pfizer Poster Symposium, N/A(N/A), N/A.